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We knew that: 1) vitamin D (VitD) deficiency is a burgeoning problem; 2) a major risk factor for 
VitD deficiency is obesity—also escalating; and 3) VitD deficiency is a side effect of some 
bariatric surgeries—the most durable treatment for obesity. We investigated the alteration of 
the VitD endocrine system in obesity as it relates to bariatric surgery patients. 
We used two proxy measures, seasonality and latitude, to assess group VitD status in the 
Nationwide Inpatient Sample (NIS). We found that adverse outcomes following bariatric surgery 
are most common from January to March when VitD status is lowest (VitD Winter). The largest 
increased odds from VitD Summer (highest VitD status) to Winter were for wound infection. The 
strongest correlations were for dehiscence and extended length of stay (LOS). Adverse 
outcomes appeared to be more common in the North with LOS reaching significance (p<0.001). 
We replicated these findings in adolescents, a growing subset in bariatric surgery. We were only 
sufficiently powered to detect a difference in LOS by latitude, yielding a significant negative 
correlation between VitD status and LOS (p=0.012). VitD supplementation, an easy and 
inexpensive treatment, could potentially mitigate risks following bariatric surgery. 
 To assess pre-operative nutritional status in bariatric candidates at our center, we measured 
vitamins A, B-12, D, E-α, E-β/γ, thiamine, folate, and iron—the deficiencies seen most commonly 
post-operatively. We found that malnutrition in one or multiple micronutrients is pervasive, 
especially VitD and iron. VitD deficiency was present in 71.4% of candidates (81.3% in blacks). 
Minorities tended to have greater malnutrition overall. The effect of pre-operative 
supplementation should be explored. 
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We investigated VitD testing and therapy in our bariatric candidates. VitD testing was lower than 
clinically indicated. At least 44.5% have more than one risk factor for VitD deficiency, since these 
patients have high melanin concentration. However, we had serum 25(OH)D concentration for 
only 18.5% of candidates. A significant proportion had not been tested but are likely to be VitD 
deficient. Candidates who were tested were not different from those who were not. We would 
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CHAPTER 1: INTRODUCTION 
OBESITY 
Obesity is a syndrome, a set of symptoms that occur together, due to excess body fat mass 
(adipose tissue). Adipose tissue is a highly active endocrine organ.7-9 Excess adipose tissue leads 
to a pro-inflammatory state by altering production of cytokines such as interleukin-1β (IL-1β), IL-
6, IL-33, and tumor necrosis factor-α (TNF- α) and adipokines such as leptin, adiponectin, and 
C1q/TNF-related protein 3 (CTRP3).7-13 Such chronic inflammation predisposes an individual to 
chronic disease, e.g. metabolic syndrome, cardiovascular disease, non-alcoholic steatohepatisis 
(fatty liver disease), and cancer.7-9;14  
PREVALENCE 
 In the United States (US), over 1/3 of adults have obesity (BMI ≥ 35 kg/m2) according to the 
National Health and Nutrition Examination Survey (NHANES) 2011-2012.15 There was no 
observed difference in obesity rates between men and women except in the subset of non-
Hispanic blacks where 56.6% of women and 37.1% of men had obesity.15 Non-Hispanic blacks 
and Hispanics are disproportionately represented in obesity rates of 47.8% and 42.5% 
respectively compared to 32.6% for non-Hispanic whites.15 Non-Hispanic Asians had the lowest 
rate of obesity at just 10.8%.15There has been some indication that current cut-points for 
obesity are not suitable for patients of Asian-descent due to higher fat mass at lower BMIs, 
which may mask a higher rate of obesity in this population.16;17 The overall rate of obesity shows 
no prospect of decline, remaining steady since NHANES 2003-2004.15 Medical care for the more 
than 78 million American adults with obesity costs an estimated $147 billion annually.18-20 
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In NHANES 2011-2012, 20.5% of 12 to 19 year olds had obesity.15 The incidence of adolescent 
obesity has more than quadrupled in the last 30 years.15 Obesity was slightly more prevalent in 
non-Hispanic black (22.1%) and Hispanic (22.6%) adolescents than non-Hispanic white 
adolescents (19.6%).21;22 Childhood obesity continues into adulthood—more than 3 in 4 obese 
children become obese adults.23;24 The highest rate of obesity is in middle-aged adults (39.5%); 
however, obesity in childhood is particularly concerning due to long term exposure to the 
chronic inflammation associated with obesity. 15 
Globally, there is a trend towards increased BMI with the greatest increase in the top 5% of the 
distribution of BMI.15 The overal rate of obesity has  more than doubled in the last 30 years, 
affecting over 600 million adults worldwide in 2014.25 The majority of human beigns on Earth 
now live in a country where overweight and obesity is a bigger killer than underweight.25 Many 
of the countries newly suffering the effects of obesity are middle and low income countries 
where underweight and other malnutrition issues are concurrent in the same population and in 
many instances within the same family or even same individual. 
COMORBIDITIES AND COMPLICATIONS 
The high prevalence of obesity and the serious comorbidities, make obesity a major public 
health concern. Obesity is a leading contributor to global mortality and the burden of disease 
associated with diabetes, cardiovascular disease, musculoskeletal disorders such as 
osteoarthritis and back pain, and some cancers.15;26;27 An increased susceptibility to infection 
such as surgical site infection and nosocomial (hospital acquired) infection is also a hallmark of 
obesity.28 Individuals with obesity who contract an infection are also more likely to succumb to 
serious complications of that infection.28 Class 3 obesity (BMI 40-49.9 kg/m2) reduces life 
expectancy by 8 to 10 years, similar to the effect of regular cigarette smoking.29 
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Childhood obesity increases the risk of hyperlipidemia and hypertension and in turn the risk for 
cardiovascular disease.25;30;31 As in adults, adolescents with obesity are more likely to be pre-
diabetic or diabetic.25;30 Approximately 215,000 Americans under the age of 20 have diabetes.32-
37 Other comorbidities that are more common in children with obesity include respiratory 
disease and poor bone mineralization.25 Obesity is also associated with decreased quality of life 
and social exclusion, which can be particularly detrimental to a developing individual and their 
mental health.23-25;38 Disability and premature death are more common in children with 
obesity.25 Since most children with obesity become obese adults, childhood obesity is likely to 
lead to the chronic diseases associated with adult obesity. 23;24 39;40 
BARIATRIC SURGERY 
Bariatric surgery is currently the most successful means of sustained long-term weight loss. 
During bariatric surgery, the digestive tract is restricted in size with focus on the stomach. There 
are various different procedures that have been developed over many decades, some of which 
also involve manipulating the intestines. 
DEVELOPMENT 
Patients who had significant portions of their stomachs or small intestines removed were 
observed to lose significant weight following such procedures, short-gut syndrome.40;41 This 
observation, followed by much trial and error (see Figure 1), ultimately led to modern bariatric 
surgery. During development, bariatric surgery was thought to function based on two basic 
principles: restriction and malabsorption. Restriction occurs by decreasing the size of the 
stomach, and therefore mechanically limiting the amount of food required to create a sense of 
fullness. Malabsorption occurs when portions of the digestive tract are bypassed (removed from 
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the digestive process), such as the small intestines, decreasing the distance and thus time to 
absorb calories from food after it is ingested. 
 
FIGURE 1 TIMELINE: DEVELOPMENT OF BARIATRIC SURGERY PROCEDURES 
 
The earliest procedures functioned exclusively through malabsorption, but resulted in numerous 
complications such as severe macronutrient deficiency. With the development of restrictive 
procedures, many of the complications were eliminated or at least mitigated; however, the 
weight loss following these procedures was limited compared to those involving malabsorption. 




With the advancement of bariatric surgery came improved understanding of the mechanism of 
action behind these procedures.  While the classic understanding of malabsorption and 
restriction still play a key role in determining the best procedure for a patient, there is another 
category of action for these procedures. This category is the physiological alteration of the 
patient. For instance if the greater curvature of the stomach is removed the neuroendocrine 
activity along the gut-brain axis is substantially altered, allowing for drastic calorie reduction 
without activation of starvation mechanisms. The specific mechanisms behind the physiological 
effect of bariatric surgery on the gut-brain axis relates to alterations in adipokines and gut 
hormones, e.g. leptin, ghrelin, and GLP-1.42 The rewards system in the brain is also affected by 
bariatric surgery with dopamine (D2) binding increasing after Roux-en-Y gastric bypass.42;43 
BARIATRIC PROCEDURES UTILIZING MALABSORPTION ALONE 
All of the subsequent bariatric surgery procedures function primarily via alteration of the 
digestive tract to cause malabsorption. Malabsorption leads to reduced calories being gleaned 
from food but also to deficiencies in micronutrients, particularly fat soluble vitamins (A, D, E, 
and K). 
1965: JEJUNOILEOSTOMY 
In the jejunoileostomy (JI) bypass procedure, the proximal jejunum is connected to the distal 
ileum—an anastomosis. The end-to-side configuration was discontinued in favor of an end-to-
end configuration, which prevented reflux into the ileum. This reflux was the route of 
suboptimal weight loss in 10% of patients.40 With improved weight loss came significant 
complications due to malabsorption of nutrients. Additionally, most patients developed atrophy 
of the intestines, leading to bacterial overgrowth (bypass enteritis) that could then lead to liver 
damage or death.44 Most mortality in the JI bypass typically occurred within 2 years post-
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operation at a rate of 4%, mostly due to liver failure.40;45;46 The high rate of serious complications 
and mortality in the JI bypass not only led to the discontinuation of the procedure itself but for 
the field of bariatric surgery to be labeled as dangerous. The field would begin to resurge in the 
late 1970's with solely restrictive procedures to avoid the stigma of the JI bypass. 
1979: BILIOPANCREATIC DIVERSION 
Biliopancreatic diversion 
(BPD) entails a significant 
reduction in the size of the 
stomach into a pouch 
(partial gastrectomy) as 
well as the creation of a 
short common intestinal 
channel (Figure 2). This 
procedure, a modification 
of the JI bypass, was 
developed with the idea 
that all portions of the gut should be included in the digestion process. The partial gastrectomy 
results in a minor restrictive effect, but the key element for weight loss is the decreased transit 
time afforded by the short common intestinal channel.46 BPD afforded approximately 70-75% 
excess weight loss in 90% of patients 1 to 8 years post-operation.47;48 Key complications included 
anemia, stomal ulcer,  protein malnutrition, and dumping syndrome.40 Dumping syndrome is 
caused by too much food, particularly simple carbohydrates, reaching the small intestine, which 
leads to symptoms such as cramps, nausea, diarrhea, heart palpitations, dizziness, and  
 
FIGURE 2 SCHEMATIC OF THE BILIOPANCREATIC DIVERSION PROCEDURE2 
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hypoglycemia. This procedure virtually eliminated bypass enteritis seen in the JI bypass. 
BARIATRIC PROCEDURES UTILIZING RESTRICTION ALONE 
The following bariatric surgery procedures function primarily via restriction of the size of the 
stomach, resulting in mechanical limitation of food intake. These procedures typically do not 
result in the severe nutritional deficiencies common with malabsorptive procedures, but they 
are less effective at producing weight loss. 40 
1971: GASTROPLASTY 
In this procedure, the stomach is divided 
into a small upper pouch and a lower 
pouch. The channel between the two was 
later reinforced in various ways. In 1980, 
the vertical banded gastroplasty (Figure 3) 
was created, which quickly became the gold 
standard for this type of procedure. The 
benefits to gastroplasty include fewer 
complications: no malnutrition risk (not malabsorptive) and low leak risk (no anastomosis).49 
There is a risk of stomal stricture, which leads to nausea, vomiting, and poor apetite.50 Excess 
weight loss was 50% in 50% of patients.51;52 Gastroplasty did not prove to be durable, as the 
restrictive pouch would open and allow to weight regain. 
  




1980: GASTRIC BANDING 
This is the only procedure in which the 
digestive tract is not surgically altered. 
Instead, a band is placed around the top 
of the stomach, which restricts the size 
of the initial portion of the stomach 
where food enters (Figure 4). The ability 
to adjust the restriction of this band 
came in 1986 with the adjustable gastric 
band (AGB). When an AGB is placed, a port is also attached under the skin of the patient. The 
port allows fluid to be delivered into the AGB via syringe to increase the pressure the AGB places 
on the stomach (restriction). The amount of restriction the AGB delivers can be altered without 
surgery or the band can be removed and the procedure completely reversed via surgery. The 
main complications associated with AGB are obstruction, band slippage, and band erosion. 
While the risk with AGB is minimal, so is the weight loss produced relative to other bariatric 
procedures.53 A meta-analysis conducted by Garb et al. in 2009 showed almost 50% excess 
weight loss with AGB in 80% of patients.42;54 While diabetes resolves in about 70% of patients 
after AGB placement, this procedure is far less effective with higher BMI patients, who have a 
remission rate of under 50%.42 This decreased effectiveness at higher BMI is likely related to the 
lower weight loss and the fact that most patients have their bands removed at 9 years post 
placement (33%) or go on to have another bariatric procedure (24%).42 Patients with lower BMIs 
may undergo the AGB while they may not be eligible for other bariatric procedures (BMI of 30 
kg/m2 with . AGB had a period of popularity with the advent of laparoscopic placement in 1993 
but has begun to fall out of favor.  
 
FIGURE 4 SCHEMATIC OF ADJUSTABLE GASTRIC BANDING1 
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1993: SLEEVE GASTRECTOMY 
Also known as the vertical sleeve 
gastrectomy (VSG), this 
procedure was originally part of 
the duodenal switch as the 
restrictive component. VSG 
involves the removal of the 
greater curvature of the stomach 
only (Figure 5), leaving the 
intestines intact. The portion of 
the stomach remaining, the 
sleeve, is about 20% of the original. VSG was often used as the first step in a staged approach to 
duodenal switch or gastric bypass in order to have higher risk patients undergo initial weight 
loss before attempting a more complicated procedure. Beginning in 2009, VSG gained popularity 
as a bariatric procedure onto itself with 60% excess weight loss at 1 to 2 year post-operation.42 
At the Johns Hopkins Center for Bariatric Surgery (JHCfBS), VSG now comprises 70-75% of all 
cases. VSG may worsen acid reflux especially in patients with a history of gastroesophageal 
reflux disease (GERD); however, nutritional deficiencies are less common except for vitamin B-
12.42 Diabetes resolves in roughly 70% of patients after the VSG procedure.42 
  




1994: GASTRIC STIMULATION 
In this procedure, electrodes are placed into the stomach wall (Figure 6) in order to stimulate 
portions of the stomach, for instance the vagal nerve, and therefore create a sense of satiety 
with less food. As with the AGB, gastric pacing has fewer risks and no permanent surgical 
alteration of the gastrointestinal tract. Gastric pacing provides even less weight loss than AGB, 
however. Results range from 20-25% excess weight loss.55 
 
FIGURE 6 DEPICTION OF AN IMPLANTED 
GASTRIC STIMULATION DEVICE56 
                      
 
FIGURE 7 DEPICTION OF THE INVESTIGATIONAL 
RESHAPE DUOTM DUAL-BALOON SYSTEM57
 
2001: MODERN ITRAGASTRIC BALLOON 
Endoluminal placement of balloon(s) inside the stomach was developed in an attempt to forgo 
surgery entirely. Intragastric balloons produce weight loss by limiting the amount of space inside 
the stomach and thus allowing for satiety with modest food consumption. These procedures are 
used alone or as initial weight loss prior to undergoing another bariatric procedure. Excess 
weight loss is about 30% at 1 year.58 Figure 7 depicts an investigation dual-balloon system, 
which has shown potential for faster results than previous systems (1/3 excess weight loss at 6 
months).59 As with gastric banding, adjustable versions of the intragastric balloon have been 
11 
 
introduced with some improvement in weight loss results, around 45% excess weight loss at 1 
year.40 All balloon systems are only temporary means of weight loss that require a commitment 
to lifestyle change. 
BARIATRIC PROCEDURES UTILIZING BOTH MALABSORPTION AND RESTRICTION 
The subsequent bariatric surgery procedures function using both malabsorption and restriction. 
They decrease the size of the stomach to limit the amount of food that can be eaten at one time 
and thus calories ingested. They will also limit the effectiveness of digestion in order to limit the 
absorption of calories (side effect being poor absorption of nutrients). These procedures tend to 
offer the greatest weight loss with a more moderate risk of side effects. 
1977: ROUX-EN-Y GASTRIC BYPASS 
In 1966, the loop gastric 
bypass (GBP) procedure 
was originally developed 
to restrict the stomach size 
(and thus meal size), 
reduce stomach acid (and 
thus digestion / absorption 
of calories), and shorten 
transit time to the small 
intestine (leading to 
dumping syndrome). After a 
few modifications, the Roux-en-Y GBP (RYGBP) was performed by creating a small stomach 
pouch and then connecting the distal part of the jejunum (the Roux limb) to this pouch, 
FIGURE 8 SCHEMATIC OF THE ROUX-EN-Y GASTRIC BYPASS PROCEDURE5 
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bypassing the duodenum (Figure 8). The duodenum is where much of the stimulation of 
hormones occurs following a meal.42 The RYGBP, compared to the loop GBP, prevented bile 
from refluxing into the stomach and made the procedure malabsorptive in addition to 
restrictive, improving weight loss outcomes to around 80% excess weight loss.42;60 Up to 90% of 
patients with diabetes  go into remission following RYGBP.42 The RYGBP has been one of the 
more prominent procedures and has stood the test of time. RYGBP is a highly effective weight 
loss procedure with lower complication rates compared to similar procedures.42 Nutritional 
deficiencies are managed with supplementation and monitored with annual laboratory testing. 
1986: BILIOPANCREATIC DIVERSION WITH DUODENAL SWITCH 
Often called simply 
duodenal switch, this is a 
modification of the BPD 
procedure. In order to 
prevent stomal ulcers and 
limit dumping syndrome, 
the pyloric sphincter was 
preserved (Figure 9). 
Additionally, the stomach 
was further restricted from 
a pouch into a tube formed 
from the lesser curvature of the stomach. The additional restriction led to greater weight loss—
80% excess weight loss was maintained after 8 years post-operation.61;62 Complications such as 
micro- and macronutrient deficiencies and diarrhea remained. In many instances, the duodenal 
switch was limited for those with class 3 obesity due to the potential complications and the 
FIGURE 9 SCHEMATIC OF THE BILIOPANCREATIC DIVERSION WITH 
DUODENAL SWITCH PROCEDURE3 
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highest mortality rate of modern bariatric procedures.42;63;64 Up to 99% of patients undergoing 
duodenal switch experience resolution of their diabetes post-operatively. This procedure gave 
rise to the VSG, which along with RY-GBP are the two most popular procedures today. 
LAPAROSCOPIC BARIATRIC SURGERY 
Minimally invasive surgery, laparoscopic surgery, was first introduced in the 1990's. In 
laparoscopic surgery a series of small incisions (1/4 to 1/2") are used instead of one long incision 
along the midline, traditional open surgery. These smaller incisions are less painful and heal 
faster and with fewer complications, e.g. infection, dehiscence, scarring, hernia. Laparoscopic 
procedures also require shorter hospital stays. Laparoscopic surgery is performed using 
instruments passed through ports in each incision while the surgery is viewed via a specialized 
camera, a laparoscope. Throughout the procedure, the abdomen of the patient is distended 
using carbon dioxide, providing sufficient room to perform the surgery. In some patients it may 
be required that a laparoscopic procedure be converted to an open procedure if scar tissue 
prevents the placement of the ports, visibility is poor, or excess bleeding occurs. 
COMPLICATIONS 
When following the candidate criteria set forth by the National Institute of Health (NIH), 
bariatric surgery is a safe, effective, and long-term treatment for obesity. The NIH guidelines 
state that patients with class 3+ obesity (BMI ≥ 40) or a BMI ≥ 35 and serious obesity-related 
comorbid conditions, who have failed traditional forms of weight loss, may be considered for 
bariatric surgery. In adolescents, it is recommended that patients have also achieved skeletal 
maturity due to concerns of nutritional deficiencies resulting from malabsorption, particularly 




Any surgery comes with risks of complications related to anesthesia, bleeding, and infection. 
Mortality is very rare in bariatric surgery (< 2%). Acute complications are more common and 
include wound infection, dehiscence, abscess, leaks, intestinal obstruction, marginal ulcers, and 
deep vein thrombosis. There are numerous strategies for minimizing these risks. To prevent 
deep vein thrombosis, for instance, anticoagulation therapy is delivered prior to surgery, 
compression is used on the legs of the patient during and after surgery, and the patient is 
encouraged to ambulate as soon as possible after surgery. 
Some chronic complications may require revision or reversal of the procedure. These included 
persistent vomiting, acid reflux, and sub-optimal weight loss. Complications following a 
revisionary procedure are more common. Patients may also develop symptomatic gallstones 
with weight loss. This can be treated with medications, but often results in the surgical removal 
of the gallbladder. It is not uncommon for a patient to have their gallbladder removed at the 
same time as the bariatric procedure. 
Most chronic complications relate to nutrition since protein and micronutrients are poorly 
absorbed following many bariatric procedures. Malabsorptive procedures function by 
decreasing nutrient absorption, which works most effectively on the absorption of fat and fat 
soluble nutrients (vitamins A, D, E, and K). Greater fat intake increases the risk of diarrhea after 
such procedures. Another side effect of over-indulgence is dumping syndrome, which occurs if a 
patient eats too much starchy or sugary food. Many patients describe this as feeling like they are 
having a heart attack and endeavor to avoid it. Beyond fat soluble nutrients, deficiency in 
vitamin B-12, folate, and iron can also arise. Malnutrition can be managed with protein shakes, 




VITAMIN D METABOLISM 
The top layer of the skin—the epidermis—is the sight of photoproduction of VitD (see Figure 
10). Upon exposure to ultraviolet-B (UVB) radiation from the sun, the precursor to VitD that is 
present in the epidermis, proVitD, is photolyzed to preVitD, which spontaneously isomerizes to 
VitD. This VitD is then transported and further processed by the liver to produce the major 
circulating metabolite, 25(OH)D. Since VitD is a steroid hormone, it is fat soluble. Thus, 25(OH)D 
accumulates in adipose tissue (fat); however, access to this stockpile is limited. 25(OH)D is used 
clinically to determine VitD status. The active form of VitD, 1,25(OH)2D, can be produced from 
25(OH)D by the kidneys or locally (extra renal) via CYP27B1, a mitochondrial enzyme. 
1,25(OH)2D is the ligand for the VitD receptor (VDR), the method of action for VitD. Extra renal 
processing of VitD into 25(OH)D and 1,25(OH)2D takes place through various cells in the body, 
most notably keratinocytes in the skin. VitD activation, production of 1,25(OH)2D, is controlled 
by a negative feedback loop systemically via the enzyme CYP24A1, which produces inactive 
metabolites such as calcitroic acid. Additionally, 1,25(OH)2D has a short half-life, about 7 hours 
versus a month for 25(OH)D.65 In the kidney, additional factors contribute to the control of VitD 






FIGURE 10 METABOLISM IN THE VITAMIN D ENDOCRINE SYSTEM 
 
Once activated into 1,25(OH)2D, VitD demonstrates autocrine and paracrine effects primarily by 
binding with the VDR and translocating into the nucleus of a cell. In the nucleus, VDR with its 
bound ligand, 1,25(OH)2D, increases or decreases expression of genes by binding to their VitD 
response elements (VDREs). Other transcriptions factors, coactivators, and corepressors are 
required for VDR to effect gene expression, e.g. the retinoid X receptor (RXR). One corepressor, 
hairless, plays a key role in the regulation of epidermal proliferation and differentiation via 
1,25(OH)2D and the VDR.66-68  
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Figure 10 shows a skin keratinocyte, but most cells throughout the body have VDRs, yielding an 
effect via active VitD on tissues well beyond bone, e.g. skin, nerves, muscles, blood vessels, and 
cells primarily involved in innate as well as adaptive immunity.69 VDREs have been discovered in 
most of the almost 2000 genes regulated by 1,25(OH)2D.69;70 A classic example of the action of 
1,25(OH)2D includes stimulation of PTH release from the parathyroid glands. PTH acts to 
increase the amount of calcium present in the blood by increasing absorption in the intestine, 
re-absorption in the kidneys, and, if necessary, releasing calcium from bone. The effect of PTH is 
dependent upon the amount of calcium and phosphorous present in the body. VitD can also 
have more immediate action via the action of 1,25(OH)2D on membrane-bound VDRs. This 
pathway has been more recently discovered, and thus is less well understood. The membrane 
bound VDR is thought to function in the action of 1,25(OH)2D in rapid signal transduction via 
protein kinase C, phospholipase C, and calcium and chloride channels.71-75 
Polymorphisms in the classic, nuclear VDR lead to systemic alteration of the VitD endocrine 
system.  For example, the Fok1 polymorphism is a single base pair change at the start site of the 
VDR, leading to translation beginning at the next start codon, 3 codons later. This results in a 
shortening of the VDR protein by 3 amino acids. The phenotype displayed in an individual with 
this Fok1 polymorphism is controversial as some individuals show poor bone mineralization 
while others suffer from rheumatoid arthritis, hypertension, and cancers, e.g. breast.69;76-81 
VDR expression in the skin is highly conserved among species including the model organism for 
developmental biology, Xenopus.82 In the major cell type of the skin, keratinocytes, 1,25(OH)2D 
bound to the VDR stimulates differentiation and limits proliferation.82  Such alteration leads to 
the graduated differentiation of the epidermis and the development of the cornified envelope, 
the lipid envelop of the skin.83-87 The cornified envelope is responsible for fluid retention and 
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protection, from radiation and other potential intruders—the barrier function of skin.83-86 
1,25(OH)2D bound to the VDR is also key  in the cascade leading to the formation of the lipids 
producing the cornified envelope.69;82;88 These varied and crucial roles is why skin is able to 
produce all elements of the VitD endocrine system without the aid of the kidneys or liver. 
A more recently discovered example of the action of 1,25(OH)2D on the classic VDR, cathelicidin, 
is shown in Figure 10. Cathelicidin (LL-37 or hCAP-18) is an antimicrobial peptide (AMP), an 
endogenous substance that functions as a broad spectrum antibiotic with antibacterial and 
antifungal properties. Cathelicidin is found in many regions of the body, including saliva, sweat, 
and skin. While pharmacological antibiotic resistance is a growing public health concern, AMPs, 
like cathelicidin, have maintained their efficacy in numerous species and even plants in part due 
to their direct action of permeabilizing the membranes of pathogens. Studies in burn victims 
show that those individuals with lower expression of AMPs are at higher risk of infection.70 
When VitD is photoproduced in the skin, high local concentrations of cathelicidin are present.70 
Injury or wounding also leads to increased production of AMPs like cathelicidin. If this response 
is swift and robust, the wound will heal without infection or long term consequences. If AMP 
production is insufficient, the wound will be vulnerable to infection, which may cause significant 
morbidity and even mortality due to sepsis or other complications. The disadvantage of an 
ineffective AMP response following injury is doubled by the secondary actions of AMPs. The 
initial action of AMPs is direct microbial killing. The secondary actions are two part 1) 
chemotaxic, meaning they signal immune cells to the site to continue to destroy invading 
pathogens, and 2) immunomodulatory. In the immunomodulatory function, AMPs stimulate the 
production of pathogen sensing receptors, Toll-like receptors, and alter the production of 
cytokines and chemokines by surrounding cells such as keratinocytes and granulocytes in order 
19 
 
to change the type of immune response.69;89 Thus, an insufficient AMP response will not be able 
to kill all pathogenic invaders but will also not properly activate the second line of defense, 
adaptive immunity. 
VITAMIN D REQUIREMENTS 
CURRENT RECOMMENDED INTAKE 
The dietary reference intakes (DRIs) for VitD were reconsidered in 2010. This was published in 
the Institute of Medicine Dietary Reference Intakes for Calcium and Vitamin D Report (2010 IOM 
Report).90;91  DRIs include Recommended Dietary Allowances (RDAs), which are 
recommendations for dietary intake of a nutrient that is designed to cover the needs of at least 
97.5% of the population, in this case the US. In the 2010 IOM Report, the RDA for VitD was set 
as 600 IU for all ages except infants aged 0 to 12 months and the elderly (71+ years of age). The 
elderly have an RDA of 800 IU.90  Infants have an adequate intake (AI) of 400 IU.90  An AI is a 
recommendation used in place of an RDA when and RDA cannot be determined because there is 
insufficient evidence to calculate and estimated average requirement. An AI is based on 
observed intakes in apparently healthy individuals. It is common to have an AI instead of an RDA 
in infants. 
While the 2010 IOM report slightly increased the RDA, much of the report was spent discussing 
the dearth of high quality research available to accurately determine the RDA for extra-skeletal 
effects of VitD. Previously, the RDA was based on data regarding the prevention of Rickets, 
severe VitD deficiency leading to bone softening and potential skeletal deformities such as 
bowed legs. The 2010 IOM report also based its recommendation solely on bone health. The 
modest increase was sparked by newer research showing the effect of VitD on parathyroid 
hormone rather than severe deficiency markers such as Rickets. This, however, essentially 
ignored a vast portion of the VitD literature. A specific call was made in the 2010 IOM report for 
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more clinical trials, especially randomized controlled trials, to be conducted to investigate the 
precise effect of VitD on extra-skeletal effects. This data would be required to incorporate extra-
skeletal outcomes into the next review of the RDA for VitD. 
DIETARY SOURCES 
Dietary sources of VitD are limited and vary greatly in composition over time and place.90;91 VitD2 
(ergocalciferol) comes from plant sources and VitD3 (cholecalciferol) from animal sources such 
as photoproduction in skin. The chief dietary source of VitD is seafood. Wild-caught salmon 
contains 500 to 1000 IU of VitD3 per 3.5 oz serving while farm raised salmon, which is more 
common in the US diet, has just 100 to 250 IU of VitD3 per 3.5 oz serving.62;91 Cooking methods 
also affect VitD content. The most destructive method of cooking for VitD is frying (≈ 50% 
remaining) while baking (≈ 90% remaining) and microwaving (≈ 99% remaining) have modest 
effects on VitD content.62 Fortified foods such as milk, cereal, orange juice, and bread supply 
minor amounts of VitD.92 
PHOTOPRODUCTION IN THE SKIN 
While dietary sources can be important, particularly in coastal regions where seafood is plentiful 
and affordable, photoproduction of VitD is the main source in most populations.92-95  
Photoproduction of VitD occurs when solar radiation in the wavelengths of 290 to 315 nm (UVB) 
hits the skin. This can occur for up to 20 minutes of exposure. UV exposure beyond 20 minutes, 
leads to degradation of both VitD and preVitD into the inactive forms lumisterol or tachysterol95. 
How much VitD is produced during sun exposure depends upon the  angle of the sun with 
minimum production occurring at a solar zenith angle around 35° and maximum production 
occurring with a 15° or lower solar zenith angle.90;96 The major contributors to the angle of the 
sun, and thus VitD photoproduction, are time of day, season, and latitude.97  Altitude can also 
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affect photoproduction since there is less ozone to absorb UVB at higher elevations.70 Beyond 
the environment, individual characteristics can affect VitD photoproduction. Melanin, skin 
pigment, acts as a natural sunscreen, absorbing UVB radiation before it can reach proVitD to 
produce VitD.70 The same effect occurs with the application of sunscreen.98 
VITAMIN D STATUS 
DEFINING DEFICIENCY AND INSUFFICIENCY 
In the literature, there is general consensus that VitD deficiency can be defined as a serum 
25(OH)D concentration of less than 20 ng/ml (50 nmol/L). There is much more debate at what 
defines VitD insufficiency (sub-optimal VitD stores). Most studies currently use less than 30 
ng/ml (75 nmol/L) or 32 ng/ml (80 nmol/L), but it has been suggested that serum 25(OH)D 
concentrations of 40 ng/ml (100 nmol/L) or even 48 ng/ml (120 nmol/L) are necessary for some 
of the extraskeletal health benefits, such as prevention of chronic disease and promotion of 
immune competence. The 2010 IOM Report concluded that a serum 25(OH)D concentration of 
15 ng/ml (40 nmol/L) should meet the requirements of about 50% of the US population and 20 
ng/ml (50 nmol/L) of about 97.5% of the population.99 Since the DRIs are aimed at covering the 
requirements of 97.5% of the US population, the 20 ng/ml (50 nmol/L) cut point for deficiency 
has been widely adopted.99 Since the 2010 IOM Report did not address extra-skeletal effects, 
they did not address a cut-point for VitD insufficiency. 
RISK FACTORS 
Since the majority of VitD status is determined by sun exposure resulting in VitD 
photoproduction100, risk factors for poor VitD status include decreased sun exposure and lower 
ability to photoproduce VitD during sun exposure. Individuals who are at risk for insufficient sun 
exposure include: shift or night shift workers, office workers, those living in northern latitudes, 
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etc. If an individual does receive sun exposure, they can still be at risk of poor VitD status if they 
have high melanin concentration (darker skin pigmentation), daily sunscreen use, veiling or 
other body covering, age (especially being elderly). 
Malabsorption may also lead to VitD deficiency. Disorders that cause poor fat absorption limit 
VitD absorption from dietary sources and supplements. Causes of malabsorption include Crohn's 
disease, Celiac disease, bowel resection, and some bariatric surgery procedures. Removal of a 
portion of the intestines may be due to cancer, enteritis, ulcers, etc. Such bowel resection limits 
the ability of the body to absorb fat and thus fat soluble nutrients (vitamins A, D, E, and K). 
A third class of risk factors includes those that disrupt the function of the VitD endocrine system. 
These include polymorphism in the VDR and kidney disease. Inability of the VDR to function 
properly will lead to VitD-deficiency-like symptoms regardless of the serum concentration of 
25(OH)D (VitD status) of the individual.  Thankfully, VDR polymorphisms are rare. Kidney disease 
is more common, however.  As the kidneys become more diseased, they become less able to 
activate 25(OH)D into 1,25(OH)2D. This too limits the function of VDR beyond VitD status. 
PREVALENCE OF DEFICIENCY AND INSUFFICIENCY 
Estimates of VitD deficiency in the US, Canada, and Europe range from 20 to 100%.101-105 In 1988 
the National Health and Nutrition Examination Survey (NHANES) began monitoring VitD status. 
In NHANES 2001-2006, 1 in 3 Americans over the age of 1 year had VitD deficiency, according to 
season adjusted serum 25(OH)D concentrations.106 Lowest prevalence of VitD deficiency was 
seen in children from 1 to 8 years of age (Figure 11).106 Prevalence of VitD deficiency significantly 
increased with age up to 14-18 years of age in females and 30 years of age in males, plateauing 




FIGURE 11 PREVALENCE OF VITAMIN D DEFICIENCY IN THE UNITED STATES BY AGE AND SEX, 2001-2006, 
SEASON ADJUSTED, ADAPTED FROM LOOKER ET AL. 2011106 
 
The data from NHANES 2001-2005 also showed that prevalence was similar in males (41.1%) 
and females (42.0%).107 The highest prevalence of VitD deficiency was in blacks (82.1%) followed 
by Hispanics (62.9%) and then whites (30.9%).107 Being black was an independent risk factor for 
VitD deficiency (OR 9.6, p<0.001).107 Those with a college education had significantly lower 
prevalence of VitD deficiency (36.7% vs. 48.2%).107 Those who were not overweight or obese as 
well as those who were in better overall health had lower prevalence of VitD deficiency with 
hypertension and hyperlipidemia  showing significant positive correlations with VitD 
deficiency.107 Obesity was estimated to increase the odds of VitD deficiency by 1.9 times, 
p<0.001.107 
National monitoring for VitD status occurs in select countries globally. In these countries, 
national VitD status falls below 75 nmol/L (30 ng/ml) for both adults (Figure 12) and 
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Argentina, show VitD inadequacy and deficiency at the country level.99 Another epicenter of 
poor VitD status appears to be in Asian countries such as India, China, and Mongolia.99 Given the 
large populations of India (1.252 billion)108 and China (1.357 billion)109 alone, the burden of VitD 
insufficiency and deficiency globally must be great and deserving public health action. 
 
 




FIGURE 13 VITAMIN D STATUS AROUND THE WORLD - CHILD / ADOLESCENT99 
 
TOXICITY 
VitD toxicity may occur if an individual has VitD hypersensitivity syndrome.110 Normal individuals 
rarely exhibit toxic levels of serum 25(OH)D due to multiple inactivation pathways including the 
negative feedback loop of 1,25(OH)2D production. Excess VitD is excreted by the liver in the bile 
and removed from the body with the feces. 
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In the rare case of VitD toxicity, intakes were estimated to be upwards of 50,000 IU per day for 
an extended period of time and resulted in serum 25(OH)D concentration around 150 ng/ml 
(375 nmol/L).110 This is an extraordinarily high concentration, considering the normative range 
of serum 25(OH)D is generally capped at 60 ng/ml (150 nmol/L), which is 2.5 times lower. 
Furthermore, 50,000 IU per day is greater than 80 times the RDA in the 2010 IOM Report. 
Toxicity requires massive daily supplementation doses over prolonged periods of time. 
PREVENTION AND TREATMENT OF DEFICIENCY IN OBESITY 
An additional complication relating to obesity and VitD status comes with supplementation. 
Given an identical dose of VitD, an obese patient will have a smaller increase in serum 25(OH)D 
concentration.111 Ekwaru et al. showed that the trajectory of the relationship of 25(OH)D 
response to VitD supplementation differed according to body weight categories. Underweight 
individuals exhibited a sharp increase in status even with lower doses while obese individuals 
required large dose to significantly increase VitD status (see Figure 14).111 In order to maintain 
VitD sufficiency in obesity, the estimated average daily supplementation is 1663 IU (95% CI: 
1538-1790), according to Ekwaru et al., compared to 28 IU (95% CI: 0-115) for a normal weight 
individual or 534 IU (95%CI: 450-619) for an overweight individual.111  Interestingly, underweight 
individuals required more VitD than normal weight individuals, estimated average daily 




FIGURE 14 THE EFFECT OF BODY WEIGHT ON THE RESPONSE OF SERUM 25(OH)D TO SUPPLEMENTATION 
 
Drincic et al. found that obese adults (BMI: 30 to 58 kg/m2) require approximately 2.5 IU per 
kilogram of body weight to increase serum 25(OH)D status by 1 ng/ml (2.5 nmol/L).111  This 
randomized, single-blind study by Drincic et al. also showed that 10,000 IU of VitD3 daily for 21 
weeks led to serum 25(OH)D concentrations ranging from 28.5 to 67.7 ng/ml (71.2 to 169.2 
nmol/L) with a median value of 48.1 ng/ml (120.2 nmol/L), well above the insufficient cut 
point.111 The baseline VitD status in these obese subjects was 23.2 ± 15.2 ng/ml (58.0 ± 38/0 
nmol/L).112 This is a 30% lower response compared to normal weight controls.112-114 Despite this 
relatively high daily dose, no cases of hypercalcuria or hypercalcemia were observed.112 These 
findings indicate that the following equation maybe helpful in determining the appropriate dose 
of VitD3 to give an obese patient: 
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Additional daily vitamin D3 (IU) = [weight (kg) x desired change in 25(OH)D (ng/ml) x 2.5] - 10 
This means that an obese adult weighing 100 kg with a serum 25(OH)D concentration of 10 
ng/ml would require supplementation with approximately  4990 IU of VitD3 daily to reach 30 
ng/ml (a 20 ng/ml increase). 
Beyond body weight, serum 25(OH)D concentration and type of supplementation (VitD2 or 
VitD3) significantly modify of the effect of supplementation on VitD status.115 The poorer the 
VitD status of an individual, the greater the effect supplementation will have on their serum 
25(OH)D concentration. In other words, 1000 IU of VitD3 given to an individual with serum 
concentration of 10 ng/ml (25 nmol/L) will have a greater impact than if that same individual 
had a baseline serum 25(OH)D concentration of 20 ng/ml (50 nmol/L). This has been shown in 
numerous studies.116-123 
VitD3 is more effective at increasing serum 25(OH)D concentration than VitD2. A systematic 
review by Zittermann et al. showed that supplementation with VitD3 resulted in an 8.08 ng/ml 
(20.19 nmol/L) greater increase compared to the same dose of VitD2.124 
THE EFFECT OF OBESITY & VITAMIN D ON THE IMMUNE SYSTEM 
SKIN AND WOUND HEALING 
Skin is the first line of defense. First, it is a physical barrier to the external world. The skin 
protects the body from a myriad of potential damages from invading pathogens to irritants. This 
barrier function is bidirectional, holding in nutrients and water. The skin is also an immune 
organ, facilitating the immune surveillance of lymphocytes and producing cytokines and other 
key substances to excite and sustain an immune response when necessary. Immune surveillance 
is a complex concept that encompasses all functions of the immune system, both innate and 
adaptive. Most often immune surveillance is a term used to denote the ability of the immune 
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system to detect, halt, and overcome a pathogen or diseased cell also known as immune 
competence. One element of immune surveillance that occurs in the skin is the production of 
compounds that are required in the event of an assault, such as antimicrobial peptides (AMPs). 
Nutritional deficiencies can compromise the barrier function of skin and can lead to decreased 
immune competence.124 VitD is one such nutrient that plays a crucial role in immunity in the 
skin. VitD aids in the barrier function of skin, in innate immunity including in the production of 
antimicrobial peptides, and in activation of adaptive immunity if necessary. VitD also aids in 
wound healing (re-epithelialization) through various mechanisms including keratinocyte 
proliferation and differentiation, matrix metalloproteinases (MMPs), and the antimicrobial 
peptide cathelicidin (LL-37 or hCAP-18).125-127 
ALTERATION OF INFLAMMATION IN OBESITY 
There are numerous changes to the structure and function of the body in obesity. The immune 
system is not resistant to these alterations. Obesity leads to excessive adipose tissue, especially 
visceral adiposity, leading to chronic low grade inflammation.128  Such chronic inflammation 
increases risk for insulin resistance, type 2 diabetes, hypertension, cardiovascular disease, fatty 
liver disease, and cancer.129 When the immune response is activated inappropriately, as in 
chronic inflammation, immunity to a real threat is dampened. This is why the immune system is 
less efficacious in obesity.130;131 
Analysis in 23 patients from the Johns Hopkins Center for Bariatric Surgery (JHCfBS) has been 
performed to evaluate differences in inflammation before and after bariatric surgery (1 year 
post-operation). In these JHCfBS patients, inflammatory markers decreased with weight 
loss,28;130;132-136 confirming the results of other studies. 
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ALTERATION OF INFLAMMATION BY VITAMIN D 
VitD in both circulating and active forms--25(OH)D and 1,25(OH)2D, respectively-- has 
widespread effects on the response and function  of the immune system.28;130;134-145 Generally, 
VitD activity stimulates steady-state conditions, meaning it stimulates anti-inflammatory 
cytokines and dampens pro-inflammatory cytokines. This is unless there is a threat present in 
which case it facilitates a robust immune response to eliminate the pathogen. The key in any 
immune response is the proper balance of cytokines in order to launch the correct form of 
attack for a specific pathogen. With insufficient VitD, the cytokine milieu will be faulty, leading 
to an inefficient or even detrimental immune response. 
IMMUNITY AND SURGICAL RISK IN OBESE INDIVIDUALS WITH POOR VITAMIN D STATUS 
Obesity is a known risk factor for adverse surgical outcomes such as poor wound healing.130 It is 
likely that obese patients will experience wound dehiscence, reopening of the wound, due to 
increased operative time, tension on the wound, and greater risk of wound infection, delaying 
wound healing.146  Numerous studies have shown that obese patients are at higher risk of 
wound infections post-operatively than normal weight controls and that this relationship 
between BMI and risk of wound infection continues even among high BMI patients.15 Chronic 
inflammation and obesity related comorbidities such as metabolic syndrome may contribute to 
this increased risk.25 Furthermore, the subcutaneous tissue of obese patients is less oxygenated 
(poorly vascularized), which may increase infection risk especially following laparoscopic 
surgery.20 
When the risk of adverse surgical outcomes in obesity is combined with that of poor VitD status, 
there is likely an additive or even synergistic effect. This means the risk and severity of such 
negative outcomes will increase, perhaps exponentially. 
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CHAPTER 2: PROXY MEASURES OF VITAMIN D STATUS CORRELATE WITH 
WOUND COMPLICATIONS AND LENGTH OF STAY AFTER BARIATRIC SURGERY 
IN THE NATIONWIDE INPATIENT SAMPLE, 2001-2010 
INTRODUCTION 
In the United States (US) National Health and Nutrition Examination Survey (NHANES) 2011-
2012, over 1/3 of adults were obese (BMI ≥ 35 kg/m2) 147-152. Obesity is a leading contributor to 
global mortality and the burden of disease associated with diabetes, cardiovascular disease, 
musculoskeletal disorders such as osteoarthritis, and some cancers.151 Class 3 obesity (BMI 40-
49.9 kg/m2) reduces life expectancy by 8 to 10 years, similar to the effect of regular cigarette 
smoking.104 
Several studies have demonstrated that most obese adults are vitamin D (VitD) insufficient (<75 
nmol/L, 30 ng/ml) or deficient (<50 nmol/L, 20 ng/ml).153;154 A large study by Vimaleswaran et al. 
found a 10% increase in Body Mass Index (BMI) was correlated with a 4% decrease in VitD 
status.125;155  The inverse relationship between BMI and VitD status is hypothesized to be due to 
sequestration of VitD by adipose tissue, reducing VitD bioavailability. 
Classically, VitD maintains bone calcification, but a more varied role has been elucidated for this 
hormone. Insufficient  VitD has been associated with susceptibility to infection, autoimmunity, 
cancer, and chronic disease.156  VitD helps regulate and shows the potential to prevent 
inflammation that instigates chronic diseases.130;157  Obesity is associated with chronic 
inflammation and increased risk of chronic diseases158;159, which may contribute to adverse 
outcomes, e.g. improper wound healing138 and wound infection104. Since VitD deficiency is also 
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associated with chronic inflammation, obese individuals with insufficient VitD have 
extraordinary risk of adverse outcomes, particularly delayed wound healing and infection due to 
the role of VitD in re-epithelialization and innate immunity.160 
Bariatric surgery is currently the most successful means of long-term weight loss. During 
bariatric surgery, the digestive tract is restricted in size focusing on the stomach. There are risks 
of complications, which may lead to extended length of stay (LOS) post-operatively. In fact, 
wound infection is the most common hospital-acquired condition following bariatric surgery.148  
Since the indications for bariatric surgery are class 3+ obesity (BMI ≥ 40 kg/m2) or class 2 obesity 
(BMI ≥ 35 kg/m2) with one serious comorbidity related to obesity, bariatric surgery patients are 
at an increased risk of most adverse surgical outcomes. VitD deficiency is likely a risk factor that 
can be easily remedied pre-operatively to reduce the number and severity of such adverse 
outcomes. 
Epidemiology has long used time of year as a proxy measurement for group VitD (VitD 
seasonality) since the majority of VitD nutriture comes from photoproduction in the skin 
exposed to solar ultraviolet-B (UVB) radiation.161 In a recent study, Kasahara et al. confirmed 
that VitD status in the US peaked in August and troughed in February.162  Thus VitD Summer, the 
time of highest VitD status, is July to September. The time of lowest VitD status is VitD Winter, 
which is January to March. This is a slight lag from traditional seasons with summer being June 
to August and winter December to February. For this study, we included the full spectrum of 
group VitD status (seasonality) by using VitD Spring (April to June) and VitD Fall (October to 
December) as an intermediary between the two extremities—VitD Summer and Winter. 
A matched pairs study comparing pre-operative gastric bypass cases to non-obese healthy 
controls, found that pre-operative bariatric patients had significantly lower VitD status and 
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elevated parathyroid hormone.162  The pairs were matched for age, sex, race/ethnicity, season 
(summer versus winter), and latitude (41°N). In summer (April to September), VitD status was 
higher than in winter (October to March). VitD seasonality has been explored as it relates to 
surgical outcomes in lung cancer patients, where patients with the highest VitD status (season 
plus diet) had better recurrence-free and overall survival.160  Bariatric surgery patients have the 
combined risk of obesity with that of undergoing a surgical procedure, an additive or perhaps 
even synergistic effect. 
Another classical proxy measure of group VitD status is latitude, as individuals closer to the 
Equator have more opportunity to photoproduce VitD. Generally, latitudes closer to the poles 
receive insufficient UVB radiation to photoproduce VitD. Webb, Kline, and Holick determined 
that skin exposed to sunlight on a cloudless day in Boston (42.2°N) from November to February 
did not photoproduce VitD.163;164  Furthermore, this lack of photoproduction occurred over a 
longer period of time farther north; in Edmonton (52°N), no photoproduction occurred from 
October to March. Conversely, VitD photoproduction occurred all year long at 34°N (Columbia, 
South Carolina) and 18°N (US Virgin Islands) 165. To study the effect of latitude, we choose the 
cut-point of 37°N (Virginia Beach, Virginia). At and above 37°N, VitD photoproduction cannot 
occur year round, meaning that deficiency is more likely during VitD Winter. Therefore hospitals 
located at or above 37°N would be included in the North cohort, the low VitD status group, and 
those located below 37°N in the South cohort, the high VitD status group. 
The aim of our study was to investigate the association between proxy measures of group VitD 





We conducted a retrospective cohort study using the Nationwide Inpatient Sample (NIS), a 
database established as part of the Healthcare Cost and Utilization Project and sponsored by the 
Agency for Healthcare Research and Quality. NIS contains all-payer data on inpatient stays from 
over 1,000 hospitals in the US each year. NIS approximates a 20% stratified sample annually, 
meaning every US hospital will be sampled at least once in any 10 year period. Our analysis was 
performed using inpatient stays from 2001 to 2010, one 10 year period. 
We restricted our analysis to bariatric surgery patients aged 18 to 65 years using International 
Classification of Diseases, 9th Revision, (ICD-9) codes. The codes 446.8 and 449.5 are sufficient 
to indicate bariatric surgery alone. The code for class 3 obesity (278.01) must be used in 
conjunction with the following codes to indicate bariatric surgery: 438.9, 443.1, 443.8, and 
443.9. Furthermore, we excluded stays including cancer (150, 151, 152, 157, and 199), ulcer 
(531 and 533), or revision codes (442.1-2, 437, 445, 446.9, 449.6-7). 
PRIMARY EXPOSURE AND OUTCOMES 
We used two classical epidemiological methods to indirectly asses group VitD status in bariatric 
surgery cases. The first technique, the primary exposure, is season, utilizing the principle that 
the vast majority of VitD status is determined by sun exposure (photoproduction). VitD season 
was defined by the following groups: VitD Summer (July to September), Winter (January to 
March), and Fall/Spring (October to December and April to June). These groups are based upon 
refined estimates of seasonality from Kasahara et al., who used serum 25(OH)D (directly 
measured individual VitD status).166;167 VitD status is highest from July to September (VitD 
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Summer) and lowest from January to March (VitD Winter). VitD status is moderate from 
October to December (VitD Fall) and April to June (VitD Spring). 
Latitude, the second classic technique, is based on the principle that individuals closer to the 
equator have more opportunity to photoproduce VitD and thus have higher VitD status as a 
group. For all analysis, we used the latitude of the sampled hospital. Latitude was computed 
based on the hospital ZIP-code from the NIS. SAS version 9.3 PROC GEOCODE (SAS Institute, 
Cary, NC) was used to convert ZIP-codes to latitudes. We created a dichotomous variable to 
distinguish between locations at or above 37°N (North) and those below 37°N (South). 
The primary outcomes were adverse surgical outcomes: non-healing wounds, wound infection, 
fascial dehiscence, suprafascial dehiscence, delayed wound healing, any complication, and 
prolonged length of hospital stay. Outcomes were determined using ICD-9 codes, grouped as in   
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Table 1. Suprafascial dehiscence is defined as the early stage of dehiscence where wound 
separation is limited to skin and subcutaneous tissue while fascial dehiscence occurs once 
wound separation has deepened to include fascia and possibly muscle. Delayed wound healing 
is defined as the occurrence of non-healing wound, wound infection, or suprafacial dehiscence. 
We also used the LOS variable in NIS to create the dichotomous variable extended LOS (> 3 days 





TABLE 1 DEFINING ADVERSE OUTCOMES FOR BARIATRIC SURGERY IN THE NATIONWIDE INPATIENT SAMPLE 
Outcome Variable ICD-9 Codes Description 
Non-healing wound 998.83 Non-healing surgical wound 
Wound infection 998.51 Infected postoperative seroma 
Fascial dehiscence 998.31 
Dehiscence of surgical wound involving the fascia 
and/or muscle 
Suprafascial dehiscence 998.3, 998.32 
Dehiscence of surgical wound involving external 
tissues, i.e. mucosa, skin, subcutaneous tissues 
Delayed wound healing 
998.3, 998.32, 
998.51, 998.83 





 All above 
 
ICD-9 = International Classification of Diseases, 9th Revision 
 
STATISTICAL ANALYSIS 
Statistical analysis was performed using Stata 12.1 (StataCorp, College Station, TX). We 
compared the occurrence of adverse outcomes over the spectrum of VitD seasonality. Since our 
outcome is dichotomous (outcome / no outcome) and our independent variables are a mix of 
continuous and categorical, Χ2 tests and logistic regression models were used. In our logistic 
regression models, we utilized Charlson Comorbity Index (CCI) to adjust for comorbidities. CCI 
interprets multiple pieces of data to predict the 10 year mortality for an individual, allowing 
comparison between myriad of diseases in a cohort with multiple comorbidities. We utilized ZIP-
code income quartile (ZIQ) to adjust for socioeconomic status (SES). ZIQ is an approximation of 
the SES of the area in which an individual lives, which is predictive of the SES of an individual. To 
determine cost per case differences, we performed linear regression using the NIS variable 
TOTCHD, total charges (cleaned). 
38 
 
Due to the differences among groups, we utilized multiple methods of analysis. Missing data 
was treated as missing at random and imputed where possible. We set α=0.05 and β = 0.20 for 
all analysis and used two-sided tests. Power calculations were performed for the primary 
outcomes (Table 2). There is sufficient power to detect a difference between VitD Winter and 
Summer for all adverse outcomes except non-healing wounds. Power decreased for latitude 
analysis with non-healing wound and wound infection being under powered. 
 
TABLE 2 POWER FOR PRIMARY OUTCOMES IN OBSERVED PROPORTIONS 
 Season  Latitude  Sex  Race  
Non-healing wound 0.0%  0.0%  0.0%  100.0% * 
Wound infection 100.0% * 0.0%  0.0%  100.0% * 
Wound dehiscence 100.0% * 93.0% * 100.0% * 100.0% * 
Wound separation 100.0% * 99.7% * 100.0% * 27.7%  
Delayed wound healing 100.0% * 99.4% * 100.0% * 100.0% * 
Any complications 100.0% * 99.4% * 100.0% * 100.0% * 
Length of stay > 3 days 100.0% * 100.0% * 11.7%  100.0% * 
         
* β < 0.20         
 
RESULTS 
We identified 932,091 bariatric surgeries in the NIS dataset from 2001-2010 (Table 3). Most 
surgeries (51%) occurred during the moderate VitD season (Spring/Fall) while 26% occurred 
during high VitD season (Summer) and 23% during low VitD season (Winter). The sampled 
hospitals were mostly urban (83.3%), which was unchanged throughout the seasons. The 
median ZIQ was 2.68 with no variation between the seasons. More surgical procedures were 
performed in the North (64.8%) and particularly during VitD Winter (p < 0.001). The majority of 
procedures were performed in women (81.2%) and in whites (74.4%). Sex was unequally 
distributed among the seasons, p=0.005. Median age was 43.0 years in all season. 
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Age (years) 43.0 ± 0.18 
 
43.0 ± 0.21 
 
43.0 ± 0.19 
 






























































* = significant at the p < 0.05 level 




Table 4 shows the demographics displayed by latitude (North versus South). We found the 
North cohort to be slightly wealthier (p<0.001) and perhaps more rural (p=0.062). The large 
proportion of females (81%) and median age (43.0 years) is consistent between geographic 
regions. The North cohort is more prominently white (77.1% versus 70.4%, p < 0.001), largely 





TABLE 4 NATIONWIDE INPATIENT SAMPLE BARIATRIC SURGERY DEMOGRAPHICS BY SEASON & LATITUDE 
  Total  North (≥37°N)  South (<37°N)  p-value 
Surgeries 932,091  603,940 (65%)  328,151 (35%)  0.000 * 
Urban 83.3%  81.7%  85.7%  0.062  
ZIP-code 
Income 
Quartile 2.68 ± 0.06  2.75 ± 0.08  2.55 ± 0.08  0.000 * 
Female 81.2%  81.3%  80.9%  0.444  
Age (years) 43.0 ± 0.18  43.0 ± 0.23  42.9 ± 0.29  0.677  
Race/ethnicity             0.000 * 
 White 74.4%  77.1%  70.4%    
 Black 12.6%  12.0%  13.6%    
 Hispanic 8.4%  6.6%  11.3%    
 Asian/PI 0.5%  0.5%  0.6%    
 
Native 
Amer. 0.6%  0.4%  0.9%    
 Other 3.4%  3.5%  3.3%    
                
* = significant at the p < 0.05 level           






Table 5 shows the frequency of adverse outcomes by season, ranging from n=72 for wound 
infection and non-healing wounds to n=367,245 for prolonged LOS. Fascial dehiscence, 
suprafascial dehiscence, delayed healing, and any complication are significantly different by 
season (Figure 15). All outcomes except non-healing wound decrease in frequency with 









FIGURE 15 SEASONALITY OF WOUND COMPLICATIONS FOLLOWING BARIATRIC SURGERY IN THE 
NATIONWIDE INPATIENT SAMPLE, 2001-2010. Vitamin D Winter ( January to March) is the time of lowest 
vitamin D status while Summer (July to September) is the highest. Spring/Fall (October to December and 
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Table 6 shows the frequency of adverse outcomes by latitude (North versus South). Prolonged 
LOS was more common in the North (p<0.001). The increased occurrence of complications in 
the North versus the South did not reach statistical significance (Figure 16). 
 




FIGURE 16 LATITUDE AND WOUND COMPLICATIONS FOLLOWING BARIATRIC SURGERY. The frequency of 
wound complications following bariatric surgery in the North cohort (≥37°N) versus the South cohort 
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Table 7 shows logistic regression for adverse outcomes and VitD seasonality as a spectrum both 
unadjusted (Model 1) and adjusted for potential confounders (Models 2 and 3). VitD seasonality 
is significantly correlated with suprafascial dehiscence, delayed wound healing, any 
complication, and prolonged LOS in all models. For each season closer to VitD Winter, the odds 
of experiencing suprafascial dehiscence (OR 1.45-1.49), delayed wound healing (OR 1.53-1.56), 
any complication (OR 1.45-1.46), and LOS (OR 1.04-1.05) significantly increases. Fascial 
dehiscence is significantly correlated with VitD seasonality in Models 1 and 2 (OR 1.30-1.33). The 
strong trend observed between VitD seasonality and wound infection is significant in Model 1 
(OR 2.50). 
 
TABLE 7 ODDS OF ADVERSE OUTCOMES FOLLOWING BARIATRIC SURGERY: SEASONALITY AS A SPECTRUM 
VitD Seasonality as a Spectrum 
            
 Model 1  Model 2  Model 3 
 
Odds 
Ratio p-value  
Odds 
Ratio p-value  
Odds 
Ratio p-value 
Non-healing wound 1.40 0.389   1.61 0.294   1.67 0.303  
Wound infection 2.50 0.018 *  1.97 0.137   1.98 0.133  
Fascial dehiscence 1.30 0.025 *  1.33 0.037 *  1.32 0.053  
Suprafascial dehiscence 1.49 0.001 *  1.45 0.022 *  1.46 0.023 * 
Delayed wound healing 1.56 < 0.001 *  1.53 0.006 *  1.55 0.006 * 
Any complication 1.46 < 0.001 *  1.45 < 0.001 *  1.46 < 0.001 * 
Length of stay > 3 days 1.05 < 0.001 *  1.04 0.001 *  1.05 < 0.001 * 
            
Model 1: Unadjusted 
Model 2: Adjusted for latitude, age, sex, and race (white vs. non-white) 
Model 3: Adjusted for latitude, age, sex, race, Charlson Comobidities Index, and ZIP-code 
income quartile 
            




We also analyzed the association of adverse outcomes comparing the highest VitD season 
(Summer) to the lowest (Winter), see Table 8. Suprafascial dehiscence (OR 1.89-2.07), delayed 
wound healing (OR 2.13-2.29), any complication (OR 1.51-2.10), and prolonged LOS (OR 1.09-
1.10) remained significant in all models. Fascial dehiscence (OR 1.82-1.92) was significant in 
Models 1 and 2. Despite strong trends, neither non-healing wound (OR 1.88-2.46) or wound 
infection (OR 4.38-7.56) reached statistical significance. Wound infection was borderline 
significant in Model 1 (OR 7.56, p=0.059). 
 
TABLE 8 ODDS OF ADVERSE OUTCOMES FOLLOWING BARIATRIC SURGERY: WINTER VS. SUMMER 
VitD Winter versus Summer 
            
 Model 1  Model 2  Model 3 
 
Odds 
Ratio p-value  
Odds 
Ratio p-value  
Odds 
Ratio p-value 
Non-healing wound 1.88 0.390   2.46 0.303   2.44 0.305  
Wound infection 7.56 0.059   4.38 0.187   4.44 0.184  
Fascial dehiscence 1.82 0.034 *  1.92 0.048 *  1.85 0.063  
Suprafascial dehiscence 2.07 0.001 *  1.89 0.019 *  1.89 0.019 * 
Delayed wound healing 2.29 < 0.001 *  2.13 0.005 *  2.13 0.005 * 
Any complication 1.51 0.007 *  2.10 < 0.001 *  2.07 < 0.001 * 
Length of stay > 3 days 1.10 < 0.001 *  1.09 < 0.001 *  1.10 < 0.001 * 
            
Model 1: Unadjusted 
Model 2: Adjusted for latitude, age, sex, and race (white vs. non-white) 
Model 3: Adjusted for latitude, age, sex, race, Charlson Comobidities Index, and ZIP-code 
income quartile 
            
* = significant at the p < 0.05 level 
 
We performed logistic analysis to determine the association of latitude with adverse outcomes 
(data not shown). Trends similar to seasonality were observed. The only significant relationship 
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with latitude was prolonged LOS (OR 1.42-159), which held after adjustment for season, age, 
sex, race, CCI, and ZIQ. 
Finally, we analyzed differences between sex (Table 9) and race (  
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Table 10). Fascial dehiscence and any complication were significant in all stratums, meaning 
there is a significantly higher risk of complications in males compared to females and whites 
compared to non-whites. Suprafascial dehiscence, fascial dehiscence, delayed wound healing, 
and any complication were significantly more likely in males. Fascial dehiscence and any 
complication were significantly more likely in whites. 
 
TABLE 9 COMPLICATIONS FOLLOWING BARIATRIC SURGERY STRATIFIED BY SEX 
 Males  Females    
  n  %   n  %  p-value 
Total            175,259              754,346     
Non-healing wound           47  0.01            64  0.01  0.496  
Wound infection           11  0.01            66  0.01  0.647  
Wound dehiscence         253  0.14          414  0.05  <0.001 * 
Wound separation         232  0.13          573  0.08  0.001 * 
Delayed wound healing         251  0.14          697  0.09  0.007 * 
Any complication         507  0.29       1,100  0.15  <0.001 * 
Length of stay > 3 days   68,984  39.4  297,743 39.5  0.846  
         





TABLE 10 COMPLICATIONS FOLLOWING BARIATRIC SURGERY STRATIFIED BY RACE 
 White  All Others     
  n  %   n  %  p-value  
Total            547,712              188,175      
Non-healing wound           44  0.01   < 11  0.00  0.515   
Wound infection           47  0.01   < 11  0.00  0.274   
Wound dehiscence         437  0.08            72  0.04  0.006 *  
Wound separation         393  0.07          122  0.06  0.663   
Delayed wound healing         478  0.09          136  0.01  0.413   
Any complication         919  0.17          203  0.11  0.017 *  
Length of stay > 3 days 205,135 37.5    66,244  35.2  0.061   
          
* p < 0.05 level          
 
DISCUSSION 
We have demonstrated a strong and graded relationship between seasonality (proxy for group 
VitD status) and adverse outcomes following bariatric surgery. Our results support the role of 
VitD in preventing complications following bariatric surgery, especially as it pertains to wound 
healing and infection as well as prolonged LOS in the hospital. The association was strongest for 
suprafascial dehiscence (p=0.001) and fascial dehiscence (p=0.034), and this relationship held 
after adjusting for latitude, age, sex, race, CCI, and SES. The largest estimated effect size was 
seen in wound infections (OR 7.56, p=0.059). Extended LOS post-operatively was also correlated 
with VitD season, p<0.001 in all models. The cost per case was $680.63 higher in VitD Winter 
than Summer and $8,961.84 in the North versus the South, some of the difference in cost likely 
results from longer hospital stays. 
Non-healing wounds occurred in just 0.01% of bariatric surgeries overall and in each season. As 
with other infrequent outcomes, a relationship may be significant in future studies directly 
measuring individual VitD status—serum 25(OH)D concentration—instead of a proxy 
measurement. Furthermore, adverse outcomes appeared to be more common in the North 
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where solar UVB radiation is less available for VitD photoproduction with prolonged LOS 
reaching statistical significance (p<0.001). 
Our analysis also revealed that suprafascial dehiscence, fascial dehiscence, delayed wound 
healing, and any complication were significantly more likely in males compared to females. This 
has been reported in other studies. 15 It is possible that wound complications occur more 
frequently in males due to decreased production of collagen, leading to a reduced capacity for 
wound healing.15 
Fascial dehiscence and any complication were significantly more likely in whites compared to 
non-whites. This seems counter to the knowledge that whites are better able to photoproduce 
VitD given the same dose of UVB radiation. However, white skin also tends to have less efficient 
barrier function. Individuals of European descent are more likely to have mutations in proteins 
required for the barrier function of skin. One such mutation occurs in the gene for filaggrin. This 
mutation has tracked with low melanin production and increased ability to photoproduce 
VitD15;26;27, which may explain why whites are more likely to experience wound complications in 
this cohort. Furthermore, VitD has been shown to impact claudins and cadherins, proteins 
required for skin integrity.15 
With the obesity epidemic on the rise, bariatric surgery will become more common. It is crucial 
to optimize the results of these surgeries by reducing alterable risk factors. The potentially 
synergistic role of VitD insufficiency and obesity on chronic inflammation may lead to increased 
risk of poor wound healing and infection. If we can supplement patients with VitD prior to 
surgery it is possible we will decrease the rates of wound infection and delayed wound healing 
and limit the LOS required post-operatively. A study examining the effect of VitD status 
directly—serum 25(OH)D concentration—instead of a proxy is the logical next step. Ultimately, a 
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randomized, controlled trial will need to be performed to establish a causal role for VitD 
insufficiency in adverse outcomes. 
LIMITATIONS 
NIS contains data at the discharge level, not the individual level. Therefore, it is possible that 
some of the individuals were readmitted for complications at a later date, and we are unable to 
account for this. This database also lacks some variables that could affect adverse outcomes or 
VitD status, such as BMI or length and difficulty of the surgical procedure. Future prospective 
studies should include these measures if possible. 
As in other bariatric surgery populations, we found smaller numbers of males and non-whites. 
Because of these low numbers, the results in these stratums were less significant than in 
females and whites, but the directionality of the relationships remained the same. This is an 
inherent issue to studying bariatric surgery at this time. 
Furthermore, VitD season is a proxy, not the direct measure of VitD status, which is serum 
25(OH)D concentration. For any individual, serum 25(OH)D could be significantly higher or lower 
than we would expect for the VitD season, e.g. if a patient took VitD supplements. It is also 
possible that there are seasonal differences in other factors that could contribute to the 
observed differences, such as winter being a time of increased exposure to infectious agents or 
that stays were extended due to snow storms. Adjusting for latitude should help account for 






The large sample size afforded by the NIS has allowed for detection of differences in adverse 
outcomes using proxy measures of VitD status where obtaining serum 25(OH)D concentration is 
not currently available. The number of surgeries has also yielded less common adverse 
outcomes like wound infection in sufficient number to detect a difference between VitD 
seasons. 
By adding latitude into NIS, we strengthened our analysis. Latitude is an additional proxy 
measure of group VitD status, allowing us to confirm the results of our analysis utilizing 
seasonality. Furthermore, latitude is a potential effect modifier of the relationship between 
seasonality and adverse outcomes. Controlling for latitude enhanced our analysis of the primary 
outcome measure, season. 
CONCLUSIONS AND RELEVANCE 
Adverse outcomes following bariatric surgery are most common from January to March when 
VitD status is lowest (VitD Winter). The largest increased odds from VitD Summer to Winter 
were for wound infection. The strongest correlations were observed for suprafascial dehiscence, 
fascial dehiscence, and extended LOS. Adverse outcomes appeared to be more common in the 
northern latitudes where solar UVB radiation is less available for VitD photoproduction with 
prolonged LOS reaching statistical significance (p<0.001). VitD supplementation, an easy and 
inexpensive treatment, may mitigate these risks and reduce the number of adverse outcomes 




We have established five of Hill's Criteria for Causation: strong (1) graded (5) correlations for a 
coherent (7), biologically plausible pathway (6), consistent with the findings of other studies (2). 
Further studies are warranted to ascertain the biological gradient at the individual level (5: dose-
response) and establish the temporality (4) and specificity (3) of the relationship.  
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CHAPTER 3: PROXY MEASURES OF VITAMIN D STATUS CORRELATE WITH 
ADVERSE SURGICAL OUTCOMES IN ADOLESCENTS UNDERGOING BARIATRIC 
SURGERY 
INTRODUCTION 
In the United States (US) National Health and Nutrition Examination Survey (NHANES) 2011-
2012, 20.5% of 12 to 19 year olds were obese (BMI ≥ 35 kg/m2).21;22 This current incidence of 
adolescent obesity is more than quadruple that 30 years prior and reflects a global trend with 
the greatest increase in the top 5% of the distribution of body mass index (BMI).30;168 Obesity 
was slightly more prevalent in non-Hispanic blacks (22.1%) and Hispanics (22.6%) than non-
Hispanic whites (19.6%).30 Childhood obesity increases the risk of hyperlipidemia and 
hypertension and in turn the risk for cardiovascular disease.32-37 As in adults, adolescents with 
obesity are more likely to be pre-diabetic or diabetic.23;24;38 In NHANES 2007-2009, 215,000 
Americans under the age of 20 had diabetes.23;24 Obesity is also associated with decreased 
quality of life and social exclusion.169 Childhood obesity typically continues through adulthood 
with more than 3 in 4 obese children becoming obese adults.170 Consequently, childhood obesity 
is likely to lead to the chronic diseases associated with adult obesity such as cardiovascular 
disease, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD).171 
Several studies have demonstrated that many obese adolescents are vitamin D (VitD) 
insufficient (<75 nmol/L, 30 ng/ml) or deficient (<50 nmol/L, 20 ng/ml). For instance, more than 
50% of Hispanic and black adolescents living in Boston were found to be deficient in VitD 171. 
Another study of obese adolescents in New York City found that 65% were VitD deficient.172 In 
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the Southern US, Olson et al. found VitD deficiency in 50% of children aged 6 to 16 years despite 
relatively plentiful sun, allowing for photoproduction of VitD.172;173 These obese children in the 
Southern US had significantly lower stores of VitD compared to lean controls (49.0 versus 67.5 
nmol/L), which would require an estimated 600 to 1200 IU increased intake daily to correct.172 
The pervasiveness of poor VitD status in obese adolescents is not limited to the US. A 
prospective study of obese adolescents in Poland found that 86% were VitD deficient with 50% 
exhibiting severe deficiency (< 25 nmol/L, 10 ng/ml).151 In this Polish cohort, VitD deficiency was 
more common in winter than summer, consistent with other studies.171-176 VitD status was also 
correlated with body and fat mass in these Polish obese adolescent.153;154;174 In a large study of 
adults, Vimaleswaran et al. found a 10% increase in Body Mass Index (BMI) was correlated with 
a 4% decrease in VitD status.125;155 Similar results have been observed in other adolescent 
cohorts as well 156. The inverse relationship between BMI and VitD status is hypothesized to be 
due to sequestration of VitD by adipose tissue, reducing VitD bioavailability. 
VitD is crucial for bone calcification especially in the developing adolescent. VitD also plays a key 
role in re-epithelialization and thus wound healing in addition to immune function, including 
elimination of infection without excessive inflammation. VitD helps to improve chronic 
inflammation, which may prevent autoimmunity, cancer, and chronic disease.130;157 Obesity is 
positively associated with such chronic inflammation177-182, which may contribute to improper 
wound healing148 and wound infection173. Therefore, insufficient VitD in obese patients greatly 
increases the risk of complications in an already at risk population. 
Without successful intervention, adolescent obesity and its associated comorbidities will likely 
lead to premature death. Currently, bariatric surgery is the most effective long-term weight loss 
treatment for adults and adolescents. 158;159 As with all surgical procedures, complications are 
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possible; however, bariatric surgery patients may be at increased risk of complications since it is 
a treatment for class 3+ obesity (BMI ≥ 40 kg/m2) and related comorbidities. 
Adult pre-operative bariatric surgery patients have been found to have significantly lower VitD 
status compared to non-obese matched controls.181-184 In one study of adolescents seeking 
bariatric surgery, VitD deficiency was found in 53% of patients while 82% were VitD 
insufficient.185 Due to obesity, comorbidities, and potentially VitD deficiency, bariatric surgery 
patients are at greater risk of most adverse surgical outcomes. Key complications in VitD 
deficient patients undergoing bariatric surgery are delayed wound healing (poor re-
epithelialization) and infection (weak innate immunity).186 
Adverse surgical outcomes and clinical outcomes in adolescents undergoing bariatric surgery 
have been found to be similar in type and frequency as in adults.183;187 Varela, Hinojosa, and 
Nguyen found significantly lower 30 day complication rates in 309 adolescents compared to 
55,192 adults undergoing bariatric surgery while acute morbidity and mortality were similar.185 
The adolescents tended to have less severe comorbidities than the adults prior to surgery and 
fewer adolescents were sent to the intensive care unit (ICU) following their bariatric 
procedure.185 In both adolescent and adult bariatric surgeries, the most prevalent procedure 
was  gastric bypass  ( 62% vs. 92%, laparoscopic and open combined).185 Adjustable gastric 
banding (AGB) and gastroplasty were both performed laparoscopicaly and in 29% and 9% of 
adolescents respectively.185 These procedures were performed more commonly in adolescents 
than adults (29% vs. 6% for AGB and 9% vs. 2% for gastroplasty). Since the AGB procedure has 
significantly lower risk of acute complications, this may contribute to the lower 30 day 
complication rates seen in these adolescents compared to the adults undergoing bariatric 
surgery. The better overall health of these adolescents is also an expected contributor. 
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Furthermore, Alqahtani et al. found adolescents undergoing laparoscopic sleeve gastrectomy 
had lower morbidity and mortality with better resolution of comorbidities than adults 
undergoing the same procedure.186 
As in adults, traditional weight loss methods such as dieting or medical management are 
modestly effective at best in treating class 3+ obesity. Multi-disciplinary centers for childhood 
obesity have been formed in an attempt to augment these traditional methods. Despite these 
resources, many adolescents with class 3+ obesity do not successfully maintain weight loss, 
likely due to family and psychosocial issues.160 Bariatric surgery offers greater weight loss and 
remission rates for metabolic syndrome, type 2 diabetes, and hypertension in both adults and 
adolescents, which is why adolescents are increasingly being referred to bariatric surgeons.148;188 
In children and adolescents, bariatric surgery has been shown to significantly decrease the risk 
of obesity in adulthood and obesity-related comorbidities such as NAFLD and sleep apnea.189;190 
Additionally, bariatric surgery in this younger cohort is more cost-effective in relation to the 
increased quality-of-life-years.191 In the just published European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) Hepatology Committee Position 
Statement, detailed indications and limitations were set forth for adolescents like those for 
adults.189 The indications boil down to: patients with a BMI ≥ 35 kg/m2 with severe obesity-
related comorbidities such as NAFLD or a BMI ≥ 40 kg/m2 with mild obesity-related 
comorbiities.189 Defining the indications for bariatric surgery in adolescents is a major step in 
improving the treatment of obesity. 
The classical epidemiological proxy measure for group VitD status is time of year (VitD 
seasonality) since photoproduction of VitD in the skin during exposure to the sun largely 
determines status.162 This extensively utilized technique has been confirmed by many studies 
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using direct measurement of VitD status--serum 25(OH)D concentration. VitD status in the US 
peaks in August and troughs in February.162 Thus, the time of highest VitD status (VitD Summer) 
is July to September. VitD Winter, the time of lowest VitD status, is January to March. These are 
somewhat delayed from traditional seasons (summer: June to August, winter: December to 
February). To include the full spectrum of group VitD status, we used VitD Spring (April to June) 
and VitD Fall (October to December) as moderate VitD season. 
Pre-operative bariatric surgery patients have been shown to have improved VitD status during 
summer compared to winter.162 We have also investigated VitD seasonality in adult bariatric 
patients. Using the Nationwide Inpatient Sample (NIS), we showed that adverse outcomes 
following bariatric surgery are most common from January to March when VitD status is lowest 
(VitD Winter), see Chapter 2. The largest increased odds from VitD Summer to Winter were for 
wound infection. The strongest correlations were observed for dehiscence and extended LOS. 
We also found that a case would cost $680.63 more in Winter compared to Summer and 
$8,961.84 in the North versus the South (Chapter 2). A likely contributor to this increased cost is 
longer hospital stays. 
Another classic epidemiological proxy measure of group VitD status is latitude since individuals 
farther from the Equator have less opportunity to photoproduce VitD. Skin exposed to sunlight 
on a cloudless day in Boston (42.2°N) from November to February did not photoproduce VitD.18 
The farther north, the longer that photoproduction cannot occur. In Edmonton (52°N), no 
photoproduction occurred from October to March. 19 VitD can be photoproduced all year long in 
more southern latitudes such as 34°N (Columbia, South Carolina) and 18°N (US Virgin Islands) 29. 
Previously, we investigated latitude in adult bariatric patients. Adverse outcomes appeared to 
be more common in the northern latitudes where solar UVB radiation is less available for VitD 
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photoproduction with prolonged LOS reaching statistical significance (p<0.001). We have chosen 
the cut-point of 37°N (Virginia Beach, Virginia). At and above 37°N, VitD photoproduction is 
limited during winter and thus VitD deficiency is more likely. We grouped hospitals located at or 
above 37°N into the North cohort, the low VitD status group, and those located below 37°N into 
the South cohort, the high VitD status group. 
The aim of our study was to investigate the association between proxy measures of group VitD 
status (seasonality and latitude) and the risk of adverse outcomes following bariatric surgery in 
adolescents. 
METHODS 
We conducted a retrospective cohort study using the Nationwide Inpatient Sample (NIS), a 
database established as part of the Healthcare Cost and Utilization Project and sponsored by the 
Agency for Healthcare Research and Quality. NIS contains all-payer data on inpatient stays from 
over 1,000 hospitals in the US each year. NIS approximates a 20% stratified sample annually, 
meaning every US hospital will be sampled at least once in any 10 year period. Our analysis was 
performed using inpatient stays from 2001 to 2010, one 10 year period. 
We restricted our analysis to bariatric surgery patients aged 13 to 21 years using International 
Classification of Diseases, 9th Revision, (ICD-9) codes. The codes 446.8 and 449.5 are sufficient 
to indicate bariatric surgery alone. The code for class 3 obesity (278.01) must be used in 
conjunction with the following codes to indicate bariatric surgery: 438.9, 443.1, 443.8, and 
443.9. Furthermore, we excluded stays including cancer (150, 151, 152, 157, and 199), ulcer 




PRIMARY EXPOSURE AND OUTCOMES 
We indirectly assessed group VitD status in bariatric surgery cases using two classical 
epidemiological proxy measures. The first measure, the primary exposure, is time of year 
(season). Season utilizes the principle that the primary determinant of VitD status is sun 
exposure (photoproduction). VitD season was defined by the following groups: VitD Summer 
(July to September), Winter (January to March), and Fall/Spring (October to December and April 
to June). VitD status is highest in VitD Summer (July to September) and lowest in VitD Winter 
(January to March). VitD status is moderate in VitD Fall (October to December) and VitD Spring 
(April to June). 
The second proxy measure, latitude, is based on the principle that individuals farther from the 
equator have less opportunity to photoproduce VitD and thus have lower VitD status as a group. 
For all analysis, we used the latitude of the sampled hospital. Latitude was computed based on 
the hospital ZIP-code from the NIS. SAS version 9.3 PROC GEOCODE (SAS Institute, Cary, NC) was 
used to convert ZIP-codes to latitudes. We created a dichotomous variable to distinguish 
between locations at or above 37°N (North) and those below 37°N (South). 
The primary outcomes were adverse surgical outcomes: non-healing wounds, wound infection, 
fascial dehiscence, suprafascial dehiscence, delayed wound healing, any complication, and 
prolonged length of hospital stay. Outcomes were determined using ICD-9 codes, grouped as in  
Table 11 Suprafascial dehiscence is defined as the early stage of dehiscence where wound 
separation is limited to skin and subcutaneous tissue while fascial dehiscence occurs once 
wound separation has deepened to include fascia and possibly muscle. Delayed wound healing 
is defined as the occurrence of non-healing wound, wound infection, or suprafacial dehiscence. 
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We also used the LOS variable in NIS to create the dichotomous variable extended LOS (> 3 days 
versus ≤ 3 days). 
 
TABLE 11 DEFINING ADVERSE OUTCOMES FOR BARIATRIC SURGERY IN THE NATIONWIDE INPATIENT 
SAMPLE 
Outcome Variable ICD-9 Codes Description 
Non-healing wound 998.83 Non-healing surgical wound 
Wound infection 998.51 Infected postoperative seroma 
Fascial dehiscence 998.31 
Dehiscence of surgical wound involving the fascia 
and/or muscle 
Suprafascial dehiscence 998.3, 998.32 
Dehiscence of surgical wound involving external 
tissues, i.e. mucosa, skin, subcutaneous tissues 
Delayed wound healing 
998.3, 998.32, 
998.51, 998.83 





 All above 
 
ICD-9 = International Classification of Diseases, 9th Revision 
 
STATISTICAL ANALYSIS 
Statistical analysis was performed using Stata 12.1 (StataCorp, College Station, TX). We 
compared the occurrence of adverse outcomes over the spectrum of VitD seasonality. Since our 
outcome is dichotomous (outcome / no outcome) and our independent variables are a mix of 
continuous and categorical, Χ2 tests and logistic regression models were used. In our logistic 
regression models, we utilized Charlson Comorbity Index (CCI) to adjust for comorbidities. CCI 
interprets multiple pieces of data to predict the 10 year mortality for an individual, allowing 
comparison between myriad of diseases in a cohort with multiple comorbidities. We utilized ZIP-
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code income quartile (ZIQ) to adjust for socioeconomic status (SES). ZIQ is an approximation of 
the SES of the area in which an individual lives, which is predictive of the SES of an individual. 
Due to the differences among groups, we utilized multiple methods of analysis. Missing data 
was treated as missing at random and imputed where possible. We set α=0.05 and β = 0.20 for 
all analysis and used two-sided tests. Power calculations were performed for the primary 
outcomes (Table 12). There is insufficient power to detect a difference between VitD Winter and 
Summer for all adverse outcomes. We had sufficient power for the latitude analysis with 
prolonged LOS only. 
 
TABLE 12 POWER FOR PRIMARY OUTCOMES IN OBSERVED PROPORTIONS 
 Season  Latitude  
Non-healing wound 0.0%  0.0%  
Wound infection 0.0%  0.0%  
Wound dehiscence 6.4%  5.4%  
Wound separation 0.0%  0.0%  
Delayed wound healing 0.0%  0.0%  
Any complications 6.4%  5.4%  
Length of stay > 3 days 11.6%  100.0% * 
     
* β < 0.20     
 
RESULTS 
We identified 15,510 adolescent bariatric surgeries in the weighted NIS dataset from 2001-2010 
( 
Table 13). Most of these surgeries (52%) occurred during the moderate VitD season (Spring/Fall) 
while 28% occurred during high VitD season (Summer) and 20% occurred during low VitD season 
(Winter). The hospitals where these surgeries occurred were mostly urban (86.4%), which was 
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unchanged throughout the seasons. The median ZIP code income quartile (ZIQ), a rough 
approximation of socio-economic status (SES), was 2.68 with no variation between the seasons. 
More surgical procedures were performed in northern latitudes (66.0% in the North). The 
majority of procedures were performed in women (79.3%) and in whites (68.3%). The median 
age was 19.2 years in all seasons. 
 




Table 14 shows the demographics displayed by latitude (North versus South). We found the 
North to be wealthier (p<0.001) and perhaps more rural (p=0.077). Both geographic regions 
were mostly females (79%) with median ages of 19.2 years. The North cohort is more 
prominently white (69.8% versus 65.8%, p = 0.021). This was also observed in our analysis of 
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adult bariatric surgeries in the NIS, but the adult cohort overall was even more predominantly 
white (74.4% versus 68.3%). The difference in race composition between the North and South is 
mostly due to fewer Hispanic adolescents (10.2% vs. 16.8%). In our analysis of adult bariatric 
surgeries in the NIS, the overall difference in race between the North and South cohort was 
similar, but there were more blacks (13.6% vs. 12.6%) and fewer Hispanics (11.3% vs. 16.8%) in 
the South than in this adolescent cohort. 
 
TABLE 14 NATIONWIDE INPATIENT SAMPLE BARIATRIC SURGERY DEMOGRAPHICS BY SEASON & LATITUDE 
    Total   North (≥37°N)   South (<37°N)   p-value 
Surgeries 15,510   10,243 (66%)   5,267 (34%)   0.000 * 
Urban 86.4%   84.8%   89.1%   0.077   
ZIPcode 
Income 
(Quartile) 2.54 ± 0.07   2.80 ± 0.11   2.57 ± 0.10   0.000 * 
Female 79.3%   80.5%   76.9%   0.023 * 
Age (years) 19.2 ± 0.10   19.4 ± 0.17   18.9 ± 0.16   0.497   
Race/ethnicity                         0.021 * 
  White 68.3%   69.8%   65.8%       
  Black 12.9%   13.1%   12.6%       
  Hispanic 12.6%   10.2%   16.8%       
  Asian/PI 0.7%   0.6%   1.0%       
  
Native 
Amer. 0.8%   0.8%   0.7%       
  Other 4.7%   5.6%   3.2%       
                                
* = significant at the p < 0.05 level                     





Table 15 shows the frequency of adverse outcomes by season, ranging from n=15 for fascial 
dehiscence to n=5,201 for prolonged LOS. Only prolonged LOS might be different by season. 
There is a non-significant trend towards decreasing frequency with increasing VitD status 
(seasonality) for fascial dehiscence and any complication. Extended LOS was less frequent in 





TABLE 15 FREQUENCY OF ADVERSE OUTCOMES FOLLOWING BARIATRIC SURGERY BY SEASON 
 
 
Table 16 shows the frequency of adverse outcomes by latitude (North versus South). Prolonged 
LOS was more common in the North (p=0.012). The increased occurrence of complications in 
the North versus the South did not reach statistical significance. 
 
TABLE 16 FREQUENCY OF ADVERSE OUTCOMES FOLLOWING BARIATRIC SURGERY BY LATITUDE 
 Total  North  South    
 n %  n %  n %  p-value 
Non-healing wound 0 0.00  0 0.00  0 0.00  -  
Wound infection 0 0.00  0 0.00  0 0.00  -  
Fascial dehiscence 15 0.10  11 0.10  < 11 0.09  0.907  
Suprafascial dehiscence 0 0.00  0 0.00  0 0.00  -  
Delayed wound healing 0 0.00  0 0.00  0 0.00  -  
Any complication 15 0.10  11 0.10  < 11 0.09  0.907  
Length of stay > 3 days 5,201 33.54  3,763 36.73  1,439 27.32  0.012 * 
 
We performed logistic regression for adverse outcomes and VitD seasonality as a spectrum both 
unadjusted (Model 1) and adjusted for potential confounders (Models 2 and 3). Model 2 
adjusted for latitude, age, sex, and race (white vs. non-white). Model 3 adjusted for the 
potential confounders in Model 2 as well as Charlson Comorbidities Index, and ZIQ. We had 
insufficient numbers to produce models for all adverse surgical outcomes except prolonged LOS. 
67 
 
VitD seasonality is non-significantly correlated with prolonged LOS in all models (OR 1.00 to 
1.07). 
We also performed logistic analysis to determine the association of latitude with adverse 
surgical outcomes. Model 1 showed a significant relationship with living in the North and 
prolonged LOS (OR 1.54, p=0.012), but the significance did not hold after adjustment for 
confounders (Models 2 and 3). 
We analyzed differences between sex and race (white versus non-white). Prolonged LOS 
appeared more prevalent in non-whites compared to whites (34.0% vs. 29.9%, p=0.110). 
Extended LOS had approximately the same prevalence in females compared to males (33.6% vs. 
33.4%, p=0.931). 
DISCUSSION 
We have previously demonstrated a strong and graded relationship between seasonality (proxy 
for group VitD status) and adverse outcomes following bariatric surgery in adults. This study is 
an attempt to replicate these results in adolescents. Our results are in line with VitD status 
potentially playing a role in preventing complications following bariatric surgery, especially in 
relation to prolonged LOS in the hospital. We were only sufficiently powered to detect a 
difference in LOS by latitude (North vs. South), which did yield a significant negative correlation 
between VitD status and prolonged LOS (p=0.012). Our other results showed a non-significant 
trend towards a negative correlation of VitD status (seasonality or latitude) and adverse surgical 
outcomes (dehiscence). 
Bariatric surgery in adolescents is sparse during the period studied (2001 to 2010), though 
becoming more established. The lower complication rate in adolescents compared to adults 
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yielded few cases of adverse surgical outcomes. Fewer complications may be due to adolescents 
simply being younger and thus healthier. It is also likely that this is the first abdominal surgery 
for these patients, which leads to a less technically difficult surgical procedure and one that is 
less likely to be converted to an open procedure. Open procedures are more likely to lead to 
complications, particularly wound complications. 
Due to insufficient numbers of surgeries as well as cases of adverse outcomes, we were unable 
to detect relationships between proxy measures of VitD status (seasonality and latitude) and 
adverse outcomes except in the case of latitude and LOS. Infrequent outcomes, such as wound 
infection, may show a significant relationship in future studies directly measuring individual VitD 
status—serum 25(OH)D concentration—instead of proxies. Furthermore, as bariatric surgery in 
adolescents becomes more prevalent and the number of surgeries increases, the number of 
cases of adverse outcomes will also increase, allowing for the detection of relationships not 
possible in the current version of the NIS dataset. 
LIMITATIONS 
Since the NIS data is amassed at the discharge level, not at the level of the individual, it is 
possible that some of the individuals were readmitted for complications at a later date. We are 
unable to account for this. This database also lacks some variables that could affect adverse 
outcomes or VitD status, such as BMI or length and difficulty of the surgical procedure. Future 
prospective studies should endeavor to include these measures. 
Fewer males and non-whites were represented in this database, which is commonly seen in 
bariatric surgery populations. Modest representation of males and non-whites is an inherent 
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issue in bariatric surgery at this time. This adolescent cohort contains a larger proportion of 
Hispanics than we have seen in adults using the NIS. 
While we utilized two different classical epidemiological proxy measure for VitD status, they are 
not direct measures of VitD status, which is serum 25(OH)D concentration. At this time, serum 
25(OH)D concentration is not available in the NIS or a similar cohort of this size. While the status 
of the group as a whole is likely being estimated well by these proxy measures, the status of any 
individual could be significantly higher or lower than we would expect for the VitD season or 
latitude, e.g. if a patient took VitD supplements. It is possible that there are additional seasonal 
differences that could contribute to the observed differences, such as winter being a time of 
increased exposure to infectious agents or that stays were extended due to snow storms. 
Adjusting for latitude should help account for effects such as snow storms. Future studies would 
benefit from determining serum 25(OH)D concentration. 
STRENGTHS 
Using a national database like the NIS provides a large sample of bariatric surgery cases. This 
may allow for detection of differences in adverse outcomes using proxy measures of VitD status 
where serum 25(OH)D concentration is at present unavailable. Replication of this study with 
additional data from future years may yield significant relationships between VitD proxy 
measures and adverse surgical outcomes. 
We strengthened our analysis by adding latitude, the second proxy measure for VitD status, into 
the NIS dataset. Adding a second proxy measure of group VitD status potentially allowed us to 
confirm the results of our analysis utilizing seasonal. Latitude is also a potential effect modifier 
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of the relationship between VitD season and adverse outcomes; therefore, controlling for 
latitude improved our analysis of season, the primary outcome measure. 
CONCLUSIONS AND RELEVANCE 
Low VitD status may be a risk factor for prolonged LOS as well as adverse surgical outcomes, 
such as dehiscence. In this study, we were only sufficiently powered to detect a difference in 
LOS by latitude (North vs. South), yielding a significant negative correlation between VitD status 
and prolonged LOS (p=0.012). Improving VitD status prior to surgery could prove to be a simple 
and cost-effective measure to decrease the risk of prolonged LOS and negative outcomes in 






CHAPTER 4: BASELINE NUTRITIONAL STATUS IN A SAMPLE OF PATIENTS 
APPROVED TO UNDERGO BARIATRIC SURGERY AT THE JOHNS HOPKINS 
CENTER FOR BARIATRIC SURGERY 
INTRODUCTION 
More than 78 million American adults have obesity 192 (BMI ≥35 kg/m2), costing an estimated 
$147 billion annually due to medical care alone 193-195. Non-Hispanic blacks and Hispanics are 
disproportionately affected with obesity rates of 47.8% and 42.5% respectively compared to 
32.6% for non-Hispanic whites 196. 
Currently, sustained long-term weight loss is most successfully obtained with bariatric surgery. 
Since the inception of modern weight loss surgery in 1977 with the development of the Roux-en 
Y gastric bypass procedure, bariatric surgeons have attempted to optimize patient care by 
improving techniques and post-operative care, including nutritional counseling 196. Pre-operative 
nutrition, on the other hand, is largely uncultivated. 
Nutritional deficiencies after surgery are commonly treated, particularly following 
malabsorptive procedures like the Roux-en Y gastric bypass. If deficiencies are present prior to 
surgery, it stands to reason that remedying them prior to surgery could be beneficial and 
certainly easier than after a malabsorptive procedure. Furthermore, malnutrition has been 
linked to adverse surgical outcomes in many studies 196. 
In this study, we assessed the baseline nutritional status of our patients who were approved and 
scheduled to undergo Roux-en Y gastric bypass. Our aim was to determine the incidence of 
micronutrient deficiencies in our patient population prior to surgery. We have focused on 
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vitamins A, B-12, D, E-α, E-β/γ, thiamine, folate, and iron as these are the micronutrient 
deficiencies we see most commonly in our post-operative patient population. 
METHODS 
We determined the nutritional status in 58 consecutive patients in this prospective, cross-
sectional study. Patients were included if they were aged 18 to 65 years and were approved to 
undergo the Roux-en Y gastric bypass procedure. As part of the standard of care and 
preparation for surgery, all patients underwent routine history and physical examination. On the 
day of surgery in the pre-operative holding area, we collected blood specimens to determine the 
nutritional status of vitamins A, B-12, D, E-α, E-β/γ, thiamine, folate, and iron (iron, total iron 
binding capacity (TIBC), and iron saturation). High pressure liquid chromatography was used for 
vitamins A, E-α, and E-β/γ, liquid chromatography with tandem mass spectrometry for thiamine, 
and immunoassays for vitamins B-12, D, and folate. Spectrophotemetry was used for iron and 
turbidity for transferrin. 
Statistical analysis was performed using Stata 12.1 (StataCorp, College Station, TX). Missing data 
was treated as missing at random. We set α=0.05 and β = 0.20 for all analysis and used two-
sided tests. Descriptive univariate and bivariate analyses were utilized to describe the nutritional 
status and comorbidities of our patient cohort. Results are expressed as median ± standard 
deviation. 
This research study was approved by our Institutional Review Board. All patients underwent 





This cohort was 77.6% female and 63.8% white (  
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Table 17). The median age was 42.5 years (range: 24 to 65 years) with no significant difference 
by sex or race/ethnicity. The males were heavier and taller. Median BMI was 46.3 kg/m2 (range: 
33.5 to 64.6 kg/m2), which varied only by race/ethnicity. Hispanics and blacks tended to present 
with higher BMIs than whites. Comorbidities were highly prevalent in this cohort with multiple 
comorbidities present in 41.4% of patients: 54% had hypertension, 42.0% were diabetic, and 
34.0% had sleep apnea. The highest rate of multiple comorbidities was seen in males, which was 
largely driven by a higher rate of diabetes and sleep apnea. 
Group status for each nutrient is reported in Table 18 (see Tables 19 and 20 for definitions of 
clinical and frank deficiency, respectively, for each nutrient). Median group status indicates 
deficiency in vitamin D (clinical: < 30 ng/ml, frank: < 20 ng/ml) in total and in all stratums. Folate 
(clinical: < 7.2 ug/L, frank: < 4 ug/L) and iron saturation (clinical: < 20%, frank < 14%) were 
significantly higher in males than females. Nutritional status was poorer in black and Hispanics 
with vitamin A (clinical: < 20 ug/dL, frank: < 10 ug/dL), vitamin D, vitamin E-α (clinical: < 5.5 
mg/L, frank: < 3 mg/L), and thiamine (clinical: < 78 nmol/L, frank: < 70 nmol/L) being significantly 
lower than in whites. Vitamin D was strongly correlated with BMI (p=0.003) and age (p=0.030). 





TABLE 17 PRE-OPERATIVE CHARACTERISTICS OF PATIENTS PRESENTING FOR BARIATRIC SURGERY 
Cohort Demographics by Sex 
  Total  Female  Male  
Demographics             
 Age (years) 42.5 ± 10.9  41.9 ± 11.0  43.0 ± 11.1  
 Female 77.6%  n = 45  n = 13  
 White 63.8%  60.0%  76.9%  
 Weight (lbs) 288.9 ± 46.6  281.5 ± 43.1  316.6 ± 50.5 * 
 Height (in.) 66.3 ± 3.4  65.2 ± 2.8  70.3 ± 2.4 * 
 BMI (kg/m2) 46.3 ± 6.9  46.63 ± 7.0  45.0 ± 6.8  
Medical History             
 Hypertension 54.0%  48.7%  72.7%  
 Diabetes 42.0%  30.8%  81.8% * 
 High cholesterol 32.7%  29.0%  45.5%  
 Gastroesophageal reflux 32.0%  30.8%  36.4%  
 Sleep apnea 34.0%  25.6%  63.6% * 
 Cancer 4.0%  0.0%  18.2% * 
 Irritable bowel syndrome 4.0%  0.0%  18.2% * 
 Cholecystectomy 14.0%  10.3%  27.3%  
 Multiple comorbidities 41.4%  33.3%  69.2% * 
              
Cohort Demographics by Race/Ethnicity 
  White  Black  Hispanic  
Demographics             
 Age (years) 43.8 ± 11.7  40.4 ± 9.2  32.7 ± 12.5  
 Female 73.0%  83.3%  100%  
 White n = 32  n = 14  n = 3  
 Weight (lbs) 283.4 ± 42.5  298.4 ± 56.6  302.7 ± 33.1  
 Height (in.) 66.8 ± 3.2  65.8 ± 3.7  62.3 ± 1.5  
 BMI (kg/m2) 44.6 ± 6.3  48.3 ± 6.8  55.0 ± 8.5 * 
Medical History             
 Hypertension 51.5%  57.1%  66.7%  
 Diabetes 45.5%  28.6%  66.7%  
 High cholesterol 37.5%  21.4%  33.3%  
 Gastroesophageal reflux 45.5%  0.0%  33.3% * 
 Sleep apnea 39.4%  21.4%  33.3%  
 Cancer 6.1%  0.0%  0.0%  
 Irritable bowel syndrome 6.1%  0.0%  0.0%  
 Cholecystectomy 15.2%  7.1%  33.3%  
 Multiple comorbidities 43.2%  38.9%  33.3%  
              





TABLE 18 PRE-OPERATIVE NUTRITIONAL STATUS OF PATIENTS PRESENTING FOR BARIATRIC SURGERY 
Nutritional Status by Sex 
 Total  Female  Male  
Vitamin A (μg/dL) 55.5 ± 21.1  54.4 ± 22.1  59.5 ± 17.4  
Vitamin B-12 (pg/ml) 451.9 ± 235.6  444.0 ± 240.6  481.3 ± 223.2  
Vitamin D (ng/mL) 16.8 ± 6.6  16.7 ± 7.1  17.3 ± 4.3  
Vitamin E-α (mg/L) 11.4 ± 4.8  11.0 ± 4.9  12.7 ± 4.6  
Vitamin E-β/γ (mg/L) 2.1 ± 0.9  2.2 ± 0.9  1.7 ± 0.7  
Thiamine (nmol/L) 133.7 ± 47.0  132.1 ± 51.5  139.6 ± 24.5  
Folate (ng/mL) 15.3 ± 6.2  14.3 ± 5.7  19.2 ± 6.7 * 
Iron (μg/dL) 75.3 ± 47.9  70.4 ± 36.0  92.6 ± 75.5  
TIBC  (μg/dL) 360.0 ± 80.1  369.9 ± 79.8  325.7 ± 74.0  
Iron saturation (%) 22.5 ± 16.8  19.4 ± 9.6  33.4 ± 28.9 * 
       
Nutritional Status by Race/Ethnicity 
 White  Black  Hispanic  
Vitamin A (μg/dL) 62.9 ± 21.1  42.9 ± 15.0  40.0 ± 2.6 * 
Vitamin B-12 (pg/ml) 434.9 ± 224.5  464.4 ± 185.0  591.0 ± 580.9  
Vitamin D (ng/mL) 18.2 ± 5.6  14.6 ± 7.8  10.7 ± 7.4 * 
Vitamin E-α (mg/L) 12.7 ± 5.3  9.0 ± 2.8  9.9 ± 1.9 * 
Vitamin E-β/γ (mg/L) 2.2 ± 1.0  1.9 ± 0.7  2.2 ± 0.1  
Thiamine (nmol/L) 150.6 ± 47.6  105.9 ± 30.3  103.0 ± 32.2 * 
Folate (ng/mL) 15.9 ± 6.1  14.3 ± 6.8  14.1 ± 0.9  
Iron (μg/dL) 83.6 ± 56.1  59.2 ± 23.3  70.0 ± 20.8  
TIBC  (μg/dL) 356.4 ± 78.7  367.7 ± 90.5  358.7 ± 33.1  
Iron saturation (%) 25.4 ± 20.0  17.0 ± 6.6  19.7 ± 7.2  
           
* p < 0.05             
 
To further explore the differences in this cohort, we dichotomized nutritional status into normal 
versus clinical deficiency (Table 19) and frank deficiency cut points (Table 20). We found 
significant malnutrition, particularly in vitamin D and iron. Deficiency was more prominent in 
blacks. Multiple micronutrient deficiency (MMND) was more common in blacks, 50.0% versus 




TABLE 19 FREQUENCY OF CLINICAL DEFICIENCY PRIOR TO BARIATRIC SURGERY BY SEX AND RACE 
                
  Cut-point  Total  Female  Male  White  Black  Hispanic  
Vitamin A < 20 ug/dL  1.7%  2.2%  0%  0%  5.6%  0%  
Vitamin B-12 < 180 ng/L  3.5%  2.2%  7.7%  2.7%  5.6%  0%  
Vitamin D < 30 ng/mL  92.9%  90.9%  100%  91.9%  93.8%  100%  
Vitamin E-α < 5.5 mg/L  5.2%  6.7%  0%  0%  16.7%  0% * 
Thiamine  < 78 nmol/L  1.8%  2.3%  0%  0%  0%  33.3% * 
Folate  < 7.2 ug/L  5.3%  6.7%  0%  2.7%  11.8%  0%  













 Male: < 65 ug/dL        
TIBC > 400 ug/dL  22.4%  26.6%  7.7%  24.3%  22.2%  0%  




≥ 3  39.7%  40.0%  38.5%  35.1%  50.0%  33.3%  
                
* p < 0.05    
                
 
TABLE 20 FREQUENCY OF FRANK DEFICIENCY PRIOR TO BARIATRIC SURGERY BY SEX AND RACE 
  Cut-point  Total  Female  Male  White  Black  Hispanic  
Vitamin A < 10 ug/dL  0%  0%  0%  0%  0%  0%  
Vitamin B-12  < 150 ng/L  1.8%  2.2%  0%  2.7%  0%  0%  
Vitamin D < 20 ng/mL  71.4%  72.7%  66.7%  64.9%  81.3%  100%  
Vitamin E-α < 3 mg/L  0%  0%  0%  0%  0%  0%  
Thiamine  < 70 nmol/L  1.8%  2.3%  0%  0%  0%  33.3% * 
Folate  < 4 ug/L  0%  0%  0%  0%  0%  0%  













 Male: < 50 ug/dL        
TIBC > 400 ug/dL  22.4%  26.6%     7.7%  24.3%  22.2%  0%  




≥ 3  20.7%  22.2%  15.4%  21.6%  22.2%  0.0%  
                






The American Society for Metabolic & Bariatric Surgery (ASMBS) reports that 80% of bariatric 
surgery patients are female 196, similar to this cohort (77.6% female). Patients are typically 
between the ages of 40 and 64 years of age 197-201; our median age was 42.5 years (IQR: 33 to 50 
years of age). The majority of surgeries are performed on whites despite higher burden of 
obesity in blacks and Hispanics. We observed this as well (63.8% white). 
The highest risk of morbidity and mortality in obesity is class 3+ obesity (BMI ≥ 40 kg/m2). Class 
3+ obesity was present in 81.0% of this pre-operative bariatric surgery cohort and was more 
frequent in blacks and Hispanics. Multiple comorbidities were less common in class 3+ obesity 
(37.5% versus 63.6% in BMI < 40 kg/m2). This is likely due to the approval process for the surgery 
itself. Patients with a BMI under 40 kg/m2 are considered candidates for bariatric surgery if they 
have "high-risk comorbid conditions such as life-threatening cardiopulmonary problems (for 
example, severe sleep apnea, pickwickian syndrome, or obesity-related cardiomyopathy) or 
uncontrolled type 2 diabetes mellitus" or "obesity-induced physical problems interfering with 
lifestyle (for example, joint disease treatable but for the obesity, or body size problems 
precluding or severely interfering with employment, family function, and ambulation)" 202-206. 
Such considerations may also explain the high rate of multiple comorbidities (41.4%) as well as 
for hypertension (54%), diabetes (42.0%), and sleep apnea (34.0%) since these likely improve 
the chance a patient will be approved for bariatric surgery. 
Males presented with the highest rate of multiple comorbidities, driven by a higher rate of 
diabetes and sleep apnea. This is despite the fact that class 3+ obesity was present in 69.2% of 
males compared to 84.4% of females. This also may be due to the approval process for bariatric 
surgery. It may be due to the differing motivations for males versus females. Females 
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undergoing bariatric surgery more frequently cite physical appearance as a motivator 207;208. 
Additionally, males have a higher rate of sleep apnea largely due to greater central adiposity 
150;151;176;209-212. Sleep apnea also adds to the metabolic syndrome, e.g. insulin resistance, 
hypertension, and dyslipidemia 213. 
While most comorbidities present in this cohort did not vary by race, the rate of 
gastroesophageal reflux disease (GERD) was significantly lower in blacks. None of the 14 blacks 
reported GERD while 45.5% of whites and 1 out of 3 Hispanics reported GER. Caucasians are 
known to be at greater risk of GERD 70. 
Racial disparities also exist in this cohort in nutritional status with blacks and Hispanics having 
significantly lower status in vitamin A, D, E-α, and thiamine. The primary deficiency in blacks and 
Hispanics is in vitamin D, which was present in all Hispanics (n=3) in this cohort. Slightly fewer 
blacks (81.3%) presented with frank vitamin D deficiency and even fewer whites (64.9%) fell into 
this category. Race is indicative of melanin concentration, and increased melanin concentration 
in the skin is a risk factor for vitamin D deficiency. Since melanin prevents ultraviolet (UV)-B 
solar radiation from photoproducing vitamin D in that skin, darker skin tones (blacks and 
Hispanics) are less able to photoproduce vitamin D given identical sun exposure. In addition to 
frank deficiency, clinical MMND was more frequent in blacks (50.0% versus 39.7% for the 
cohort). 
Overall, vitamin D and iron were the chief nutritional deficiencies found in pre-operative 
bariatric surgery patients. Vitamin D was strongly correlated with BMI (p=0.003) and age 
(p=0.030), a common finding in the literature 149-152;209-212. Vitamin A strongly correlated with age 
(p=0.001) and number of comorbidities (p=0.003). Since vitamin A is an acute phase reactant, 
one would expect illness and chronic inflammation to correlate with vitamin A status. 
80 
 
The National Health and Nutrition Examination Survey (NHANES) 2003-2006 was used to 
develop the body iron model, which predicts that 9% of females will have iron deficiency in the 
US population 149;152. The rate of iron deficiency in our cohort is higher than this prediction. We 
found 22.4% to 56.9% deficiency in all patients. This breaks down to 26.6% to 62.2 % females 
and 7.7% to 38.5% males. 36.2% of our cohort was deficient with serum iron concentration 
while TIBC shows 22.4% were deficient. An interesting finding is that more males were deficient 
than females, according to serum iron concentration (38.5% vs. 35.6%). 
The median vitamin D status in this cohort indicates frank deficiency as a group and in each 
subgroup (stratified by sex and race). According to NHANES 2005–2006 survey, the mean serum 
25(OH)D in the United States is 22.4 ng/ml (56 nmol/L) 147-152, higher than the 16.8 ng/ml (42 
nmol/L) mean in this cohort of pre-operative bariatric surgery patients . Obesity is a known risk 
factor for vitamin D deficiency due to an inherent need for more VitD to exhibit the same serum 
25(OH)D concentration 196. This greater need is due to sequestration of this fat soluble hormone 
in adipose tissue 104;214. As fat mass increases, an individual will require greater amounts of VitD 
(via photoproduction from sun exposure, dietary intake, and/or supplementation). 
LIMITATIONS 
Limited numbers of males and non-Caucasians were included in this study. A larger study would 






To our knowledge, this is the most extensive study of pre-operative nutritional status in patients 
undergoing Roux-en-Y gastric bypass. Our population is generalizable to most academic Centers 
of Excellence with the majority of patients being female and Caucasian. Additionally, our study 
assessed a broad range of micronutrients and identified two chief deficiencies for future study: 
iron and vitamin D. This is consistent with other studies. 
CONCLUSIONS 
Malnutrition in one or multiple micronutrients is pervasive in this pre-operative bariatric cohort, 
chiefly in vitamin D and iron. Minorities tended to have greater malnutrition. Further studies 
should be carried out to determine whether these deficiencies increase the risk of adverse 
surgical outcomes. Furthermore, the effect of pre-operative supplementation, especially vitamin 




CHAPTER 5: THE STATE OF VITAMIN D TREATMENT IN BARIATRIC SURGERY 
PATIENTS: A PROSPECTIVE CHART REVIEW OF PRE-OPERATIVE BARIATRIC 
SURGERY PATIENTS AT THE JOHNS HOPKINS CENTER FOR BARIATRIC 
SURGERY 
INTRODUCTION 
Obesity is a known risk factor for vitamin D (VitD) deficiency and fat mass correlates with VitD 
status 150;175;215. Thus, patients with morbid obesity seeking surgical weight loss treatment are at 
high risk of poor VitD status. In patients approved to undergo bariatric surgery, reports of VitD 
deficiency (< 20 ng/ml, 50 nmol/L) range from 40 to 68.1% according to the 2009 American 
Society for Metabolic & Bariatric Surgery Medical Guidelines 130;147;156;157. Risks of VitD deficiency 
include increased susceptibility to infection, autoimmunity, cancer, chronic disease, and even 
mental disorder 112. We have found VitD deficiency in 71.4% of a sample of our patients at the 
Johns Hopkins Center for Bariatric Surgery (JHCfBS).  
In addition to frank deficiency, VitD insufficiency (< 30 ng/ml, 75 nmol/L) is also prevalent in pre-
operative bariatric surgery patients. VitD insufficiency increases the risk of many complications 
and diseases already highly prevalent in obesity such as metabolic disorder 216 and adverse 
surgical outcomes 104. According to a previous study, the vast majority (92.9%) of our patients at 
JHCfBS have VitD insufficiency prior to undergoing bariatric surgery (Chapter 4). 
Once a patient has been identified as being VitD deficient or insufficient, they can be treated 
with VitD supplementation. The best regime for supplementation has changed over time and is 
still under debate. Cholecalciferol (VitD3) is more effective at increasing serum 25(OH)D 
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concentration than ergocalciferol (VitD2). A systematic review by Zittermann et al. showed that 
supplementation with VitD3 resulted in an 8.08 ng/ml (20.19 nmol/L) greater increase compared 
to the same dose of VitD2.20 Despite the reduced efficacy of VitD2 most pharmaceutical 
preparations of VitD in the United States (US) are VitD2. VitD2 is the plant version of VitD and it is 
not found in significant concentration in the human body without supplementation. 
Pharmaceutical preparation of VitD2 are often used for high dose, medically monitored, VitD 
supplementation in VitD deficient and insufficient patients. Contrastingly, most over-the-
counter VitD supplements contain VitD3, the form naturally produced in the human body during 
sun exposure. 
Our practice requests serum 25(OH)D testing from the Primary Cary Physician (PCP) of each 
bariatric surgery candidate if testing has been run pre-operatively. The aim of our study is to 
assess the extent to which our bariatric surgery candidates, a high risk population for VitD 
deficiency and insufficiency, have their VitD status tested by their PCP prior to bariatric surgery. 
Our secondary aim is to assess whether and how our patients are being treated for VitD 
deficiency and insufficiency pre-operatively. 
METHODS 
We reviewed the electronic medical records of all pre-operative bariatric surgery patients at our 
center with upcoming appointments from November 2014 through January 2015 (3 months). In 
order to assess whether VitD testing was performed by PCPs, we collected serum 25(OH)D 
concentration and test date or test order date if the testing was still pending. In order to assess 
treatment, we collected supplementation information including multivitamin and calcium 
supplements containing VitD. We collected information about type of VitD (VitD3 or VitD2) as 




The majority of our pre-operative patients were female (83.0%, p<0.001) with an almost 50/50 
split between whites (48.7%) and blacks (44.5%) with a small number of other races (6.4%), 
p<0.001 (Table 21 and   
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Table 22). The median age was 43 years with males tending to be older than females (49 ± 11 
years vs. 42 ± 13 years, p=0.002). Age did not vary significantly by race. Median BMI was 46.3 
kg/m2; BMI did not significantly differ by sex or race. Male surgical candidates were more likely 
to be white (71.1%, p<0.001) and black candidates were most likely to be female (90.7%, 
p=0.001-0.004). 
 
TABLE 21 DEMOGRAPHICS OF BARIATRIC SURGERY CANDIDATES BY SEX 
  Total  Female  Male  p-value 
Candidates 265  220 (83.0%)  45 (17.0%)  < 0.001 * 
Age (years) 43 ± 13  42 ± 13  49 ± 11  0.002 * 
BMI (kg/m2) 46.3 ± 10.5  47.3 ± 10.3  43.5 ± 11.0  0.417  
Procedure       0.175  
 GBP 96 (35.6%)  80 (36.4%)  16 (35.6%)  0.870  
 VSG 148 (55.8%)  123 (55.9%)  25 (55.6%)  0.941  
 Undecided 20 (7.6%)  17 (7.7%)  3 (6.7%)  0.858  
 AGB 1 (< 1%)  0  1 (2.2%)  --  
Approach       0.952  
 Laparoscopic 207 (78.1%)  172 (78.2%)  35 (77.8%)  0.890  
 Open 58 (21.9%)  48 (21.8%)  10 (22.2%)  0.942  
Race       0.004 * 
 White 129 (48.9%)  97 (44.3%)  32 (71.1%)  < 0.001 * 
 Black 118 (44.7%)  107 (48.9%)  11 (24.4%)  < 0.001 * 
 Other 17 (6.4%)  15 (6.8%)  2 (4.4 %)  0.630  
          
* = significant at the p < 0.05 level      





TABLE 22 DEMOGRAPHICS OF BARIATRIC SURGERY CANDIDATES FROM BY RACE 
 
 
The most popular procedure was the vertical sleeve gastrectomy (VSG), 55.8%, followed by the 
gastric bypass (GBP), 35.6%, with 7.6% of patients still undecided on a procedure and 1 
interested in the adjustable gastric band (AGB). More than 3 out of 4 of all procedures were 
planned to be performed laparoscopicaly (with the possibility of conversion to open) while 
almost 22% were to be performed using the traditional open method from the start. There was 
no significant difference in procedure or approach by sex or race (Figure 17Figure 18). When 
comparing whites to blacks, more of the VSG candidates were white (55.1% vs. 44.9%, p=0.016) 





FIGURE 17  DEMOGRAPHICS OF CANDIDATES FOR BARIATRIC SURGERY BY PROCEDURE TYPE 
 
 
FIGURE 18 DEMOGRAPHICS OF CANDIATES FOR BARIATRIC SURGERY BY PROCEDURE TYPE 
 
Only 18.5% of all candidates had VitD status testing results on file with orders pending for an 
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(Table 23 and Figure 19). Of the results on file, the median serum 25(OH)D concentration was 
21.5 ± 15.3 ng/ml. Neither availability of VitD status or serum 25(OH)D concentration varied 
significantly by sex or race, (Table 24 and Figure 19 and Figure 20). No significant correlation was 
observed between any VitD related history, treatment, or supplementation with sex or race. 
 
TABLE 23 VITAMIN D STATUS TESTING, HISTORY, AND TREATMENT BY SEX 
  Total  Female  Male  p-value 
Candidates 265  220 (83.0%)  45 (17.0%)  < 0.001 * 
Laboratory Testing         
 Serum 25(OH)D (ng/ml) 21.5 ± 15.3  21.9 ± 15.8  21.0 ± 10.4  0.440  
 25(OH)D available 49 (18.5%)  44 (20.0%)  5 (11.1%)  0.163  
 25(OH)D pending 9 (4.2%)  8 (4.6%)  1 (2.5%)  0.559  
History & Treatment         
 VitD defic. history 58 (22.0%)  52 (23.8%)  6 (13.3%)  0.121  
 High dose therapy 31 (11.7%)  27 (12.3%)  4 (8.9%)  0.520  
 Daily dose therapy 42 (15.8%)  38 (17.3%)  4 (8.9%)  0.161  
 Cholecalciferol (VitD3) 45 (17.0%)  41 (18.6%)  4 (8.9%)  0.113  
 Ergocalciferol (VitD2) 30 (11.3%)  27 (12.3%)  3 (6.7%)  0.279  
 Multivitamin 72 (27.2%)  65 (29.6%)  7 (15.6%)  0.055  
 Calcium with VitD 22 (8.3%)  18 (8.2%)  4 (8.9%)  0.876  
          
* = significant at the p < 0.05 level        





FIGURE 19 AVAILABILITY OF VITAMIN D STATUS IN BARIATRIC SURGRY CANIDATES 
 














Female Male White Black Other
Demographic Characteristic
Availability of Vitamin D Status in Bariatric 
Surgery Candidates




FIGURE 20 VITAMIN D STATUS IN BARIATRIC SURGERY CANIDATES 
 
Patients who had their VitD status tested did not differ from those who were not tested by age, 
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Table 25). Those who had testing on file were more likely to have a history of VitD deficiency 
(65.3% vs. 12.2%, p<0.001). Tested candidates were more likely to be on high dose VitD therapy 
(26.5% vs. 8.3%, p<0.001), and take daily VitD (28.6% vs. 13.0%, p=0.007), see Figure 21. 
Patients who had testing were more likely to be taking VitD2 (24.5% vs. 8.3%, p=0.001) over 
VitD3 (26.5% vs. 14.8%, p=0.049), see Figure 22. There was no significant relationship with intake 





TABLE 25 CANDIDATES TESTED FOR VITAMIN D STATUS VERSUS THOSE NOT TESTED 
  Total  Tested  Not Tested  p-value 
Candidates 265  49 (18.5%)  216 (81.5%)  < 0.001 * 
 Age (years) 43 ± 13  46 ± 14  42 ± 13  0.637  
 Female 83.0%  89.8%  81.5%  0.162  
 BMI (kg/m2) 46.3 ± 10.5  46.5 ± 9.2  46.0 ± 10.7  0.713  
Procedure       0.673  
 GBP 96 (35.6%)  20 (40.8%)  76 (35.2%)  0.251  
 VSG 148 (55.8%)  27 (55.1%)  121 (56.0%)  0.825  
 Undecided 20 (7.6%)  2 (4.1%)  18 (8.3%)  0.496  
 AGB 1 (< 1%)  0  1 (< 1%)  --  
Approach       0.782  
 Laparoscopic 207 (78.1%)  39 (79.6%)  168 (77.8%)  0.533  
 Open 58 (21.9%)  10 (20.4%)  48 (22.2%)  0.742  
Race       0.941  
 White 129 (48.9%)  23 (46.9%)  106 (49.3%)  0.586  
 Black 118 (44.7%)  23 (46.9%)  95 (44.2%)  0.555  
 Other 17 (6.4%)  3 (6.1%)  14 (6.5%)  0.947  
History & Treatment         
 VitD defic. history 58 (22.0%)  32 (65.3%)  26 (12.2%)  < 0.001 * 
 High dose therapy 31 (11.7%)  13 (26.5%)  18 (8.3%)  < 0.001 * 
 Daily dose therapy 42 (15.8%)  14 (28.6%)  28 (13.0%)  0.007 * 
 Cholecalciferol (VitD3) 45 (17.0%)  13 (26.5%)  32 (14.8%)  0.049 * 
 Ergocalciferol (VitD2) 30 (11.3%)  12 (24.5%)  18 (8.3%)  0.001 * 
 Multivitamin 72 (27.2%)  15 (30.6%)  57 (26.4%)  0.548  
 Calcium with VitD 22 (8.3%)  4 (8.2%)  18 (8.3%)  0.969  
          
* = significant at the p < 0.05 level        
BMI = body mass index, GBP = gastric bypass, VSG = vertical sleeve gastrectomy, AGB = adjustable 








FIGURE 22 TYPE OF VITAMIN D GIVEN BY VITAMIN D TESTING AND HISTORY OF DEFICIENCY 
 
Surgical candidates with a history of VitD deficiency were not different from those without a 
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Those with a history of VitD deficiency were more likely to be on high dose VitD therapy (44.8% 
vs. 2.5%, p<0.001) and were more likely to be taking VitD2 (41.4% vs. 2.9%, p<0.001) over VitD3 
(25.9% vs. 14.6%, p=0.045), see Figure 21 Figure 22. There was no significant relationship with 
intake of a multivitamin or calcium with VitD. There was a borderline significant trend towards 
lower serum 25(OH)D concentration (poorer VitD status) in those with a history of VitD 
deficiency compared to those with no recorded history of VitD deficiency (21.0 ± 11.4 ng/ml vs. 
27.0 ± 20.1 ng/ml, p=0.065), see Figure 23. Candidates with a history of VitD deficiency were 
significantly more likely to have serum 25(OH)D on file (55.2% vs. 8.3%, p<0.001) and pending 
(15.4% vs. 2.7%, p=0.002). 
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TABLE 26 CANDIDATES WITH A HISTORY OF VITAMIN D DEFICIENCY VERSUS THOSE WITHOUT A HISTORY 





History  p-value 
Candidates 265  58 (21.9%)  204 (77.0%)  < 0.001 * 
 Age (years) 43 ± 13  45 ± 14  43.0 ± 13  0.747  
 Female 83.0%  89.7%  81.0%  0.121  
 BMI (kg/m2) 46.3 ± 10.5  47.3 ± 10.0  45.7 ± 10.6  0.534  
Procedure       0.523  
 GBP 96 (35.6%)  24 (41.4%)  72 (35.1%)  0.196  
 VSG 148 (55.8%)  32 (55.2%)  115 (56.1%)  0.825  
 Undecided 20 (7.6%)  2 (3.4%)  17 (8.3%)  0.427  
 AGB 1 (< 1%)  0  1 (< 1%)  --  
Approach       0.428  
 Laparoscopic 207 (78.1%)  43 (74.1%)  162 (79.0%)  0.084  
 Open 58 (21.9%)  15 (25.9%)  43 (21.0%)  0.360  
Race       0.899  
 White 129 (48.9%)  29 (50.0%)  100 (49.0%)  0.820  
 Black 118 (44.7%)  26 (44.8%)  90 (44.1%)  0.878  
 Other 17 (6.4%)  3 (5.2%)  14 (6.9%)  0.782  
Laboratory Testing         
 Serum 25(OH)D (ng/ml) 21.5 ± 15.3  21.0 ± 11.4  27.0 ± 20.1  0.065  
 25(OH)D available 49 (18.5%)  32 (55.2%)  17 (8.3%)  < 0.001 * 
 25(OH)D pending 9 (4.2%)  4 (15.4%)  5 (2.7%)  0.002 * 
History & Treatment         
 High dose therapy 31 (11.7%)  26 (44.8%)  5 (2.4%)  < 0.001 * 
 Daily dose therapy 42 (15.8%)  12 (20.7%)  30 (14.6%)  0.266  
 Cholecalciferol (VitD3) 45 (17.0%)  15 (25.9%)  30 (14.6%)  0.045 * 
 Ergocalciferol (VitD2) 30 (11.3%)  24 (41.4%)  6 (2.9%)  < 0.001 * 
 Multivitamin 72 (27.2%)  15 (25.9%)  57 (27.8%)  0.770  
 Calcium with VitD 22 (8.3%)  3 (5.2%)  19 (9.3%)  0.320  
          
* = significant at the p < 0.05 level        
BMI = body mass index, GBP = gastric bypass, VSG = vertical sleeve gastrectomy, AGB = adjustable 





Candidates for bariatric surgery on high dose VitD therapy did not differ from those on daily VitD 
therapy by age, sex, or BMI, (Table 27). Patients on daily VitD were more likely to be white 
(58.5% vs. 49.2%, p=0.032) while those on high dose VitD were more likely to be black (51.6% vs. 
39.0%, p=0.005). There was a trend toward more patients on high dose VitD to be seeking GBP 
(48.4% vs. 39.0%, p=0.059) and for those on daily VitD to be seeking VSG (56.1% vs. 45.2%, 
p=0.008). Surgical approach varied with VitD therapy, as a high proportion of patients on high 
dose VitD were to have laparoscopic surgery (80.6%) while a smaller proportion on daily VitD 
were slated for laparoscopy (65.8%, p<0.001). Candidates on high dose VitD therapy were more 
likely to have a history of VitD deficiency (83.9% vs. 26.8%, p<0.001). High dose therapy was 
mostly delivered as VitD2 (87.1%, p<0.001) while daily dosing was almost exclusively VitD3 
(95.1%, p<0.001). There was no significant relationship between high dose therapy or daily 
dosing in terms of testing for VitD status. Serum 25(OH)D concentration was border-line 
significantly higher in daily versus high dose VitD (28.0 ± 20.9 ng/ml vs 21.0 ± 9.4 ng/ml, 
p=0.077) , see Figure 23. One patient whose main VitD therapy was high dose also took daily 




TABLE 27 CANDIDATES ON HIGH DOSE VITAMIN D THERAPY VERSUS DAILY VITAMIN D 
  Total  
High Dose 
VitD  Daily VitD  p-value 
Candidates 265  31 (11.7%)  41 (15.5%)  0.192  
 Age (years) 43 ± 13  42 ± 13  47 ± 14  0.108  
 Female 83.0%  87.1%  90.2%  0.674  
 BMI (kg/m2) 46.3 ± 10.5  49.6 ± 10.9  47.7 ± 9.8  0.367  
Procedure       0.654  
 GBP 96 (35.6%)  15 (48.4%)  16 (39.0%)  0.059  
 VSG 148 (55.8%)  14 (45.2%)  23 (56.1%)  0.008 * 
 Undecided 20 (7.6%)  2 (6.4%)  2 (4.9%)  0.756  
 AGB 1 (< 1%)  0  0  --  
Approach       0.165  
 Laparoscopic 207 (78.1%)  25 (80.6%)  27 (65.8%)  < 0.001 * 
 Open 58 (21.9%)  6 (19.4%)  14 (34.2%)  0.018 * 
Race       0.531  
 White 129 (48.9%)  14 (49.2%)  24 (58.5%)  0.032 * 
 Black 118 (44.7%)  16 (51.6%)  16 (39.0%)  0.005 * 
 Other 17 (6.4%)  1 (3.2%)  1 (2.4%)  0.829  
Laboratory Testing         
 Serum 25(OH)D (ng/ml) 21.5 ± 15.3  21.0 ± 9.4  28.0 ± 20.9  0.077  
 25(OH)D available 49 (18.5%)  13 (41.9%)  13 (31.7%)  0.378  
 25(OH)D pending 9 (4.2%)  1 (5.6%)  3 (10.7%)  0.545  
History & Treatment         
 VitD defic. history 58 (22.0%)  26 (83.9%)  11 (26.8%)  < 0.001 * 
 High dose therapy 31 (11.7%)  31 (100%)  0  < 0.001 * 
 Daily dose therapy 42 (15.8%)  1 (3.2%)  41 (100%)  < 0.001 * 
 Cholecalciferol (VitD3) 45 (17.0%)  5 (16.1%)  39 (95.1%)  < 0.001 * 
 Ergocalciferol (VitD2) 30 (11.3%)  27 (87.1%)  2 (4.9%)  < 0.001 * 
 Multivitamin 72 (27.2%)  9 (29.0%)  21 (51.2%)  0.059  
 Calcium with VitD 22 (8.3%)  2 (6.4%)  8 (19.5%)  0.113  
          
* = significant at the p < 0.05 level        
BMI = body mass index, GBP = gastric bypass, VSG = vertical sleeve gastrectomy, AGB = adjustable 





In patients receiving VitD2 versus VitD3, there was no significant variation in age, sex, BMI, or 
surgical approach, (Table 28). The group receiving VitD2 had border-line significantly higher BMI 
(50.6 ± 11.0 kg/m2 vs. 46.6 ± 8.9 kg/m2, p=0.059), see Figure 23. Those taking VitD2 were more 
likely to be black (53.3% vs. 35.7%, p<0.001) and those taking VitD3 were more likely to be white 
(59.5% vs. 43.3%, p<0.001). Patients on VitD2 were mostly seeking GBP (53.3% vs. 38.1%, 
p=0.002) while those on VitD3 were mostly seeking VSG (57.1% vs. 40.0%, p<0.001). Those on 
VitD2 were more likely to have a history of VitD deficiency in their record (80.0% vs. 31.0%, 
p<0.001) and be on high dose VitD therapy (90.0% vs. 4.8%, p<0.001). Those on VitD3 were less 
likely to have a history of VitD deficiency in their record (31.0% vs. 80.0%, p<0.001) and more 




TABLE 28 CANDIDATES ON ERGOCALCIFEROL (VITAMIN D2) VERSUS CHOLECALCIFEROL (VITAMIN D3) 
  Total  VitD2  VitD3  p-value 
Candidates 265  30 (11.3%)  42 (15.8%)  0.071  
 Age (years) 43 ± 13  42 ± 13  46 ± 14  0.245  
 Female 83.0%  90.0%  92.9%  0.665  
 BMI (kg/m2) 46.3 ± 10.5  50.6 ± 11.0  46.6 ± 8.9  0.059  
Procedure       0.358  
 GBP 96 (35.6%)  16 (53.3%)  16 (38.1)  0.002 * 
 VSG 148 (55.8%)  12 (40.0%)  24 (57.1%)  < 0.001 * 
 Undecided 20 (7.6%)  2 (6.7%)  2 (4.8%)  0.691  
 AGB 1 (< 1%)  0  0  --  
Approach       0.619  
 Laparoscopic 207 (78.1%)  23 (76.7%)  30 (71.4%)  0.092  
 Open 58 (21.9%)  7 (23.3%)  12 (28.6%)  0.372  
Race       0.330  
 White 129 (48.9%)  13 (43.3%)  25 (59.5%)  < 0.001 * 
 Black 118 (44.7%)  16 (53.3%)  15 (35.7%)  < 0.001 * 
 Other 17 (6.4%)  1 (3.3%)  2 (4.8%)  0.772  
Laboratory Testing         
 Serum 25(OH)D (ng/ml) 21.5 ± 15.3  19.0 ± 10.2  31.5 ± 19.7  0.027 * 
 25(OH)D available 49 (18.5%)  12 (40.0%)  12 (28.6%)  0.317  
 25(OH)D pending 9 (4.2%)  1 (5.6%)  3 (10.0%)  0.590  
History & Treatment         
 VitD defic. history 58 (22.0%)  24 (80.0%)  13 (31.0%)  < 0.001 * 
 High dose therapy 31 (11.7%)  27 (90.0%)  2 (4.8%)  < 0.001 * 
 Daily dose therapy 42 (15.8%)  3 (10.0%)  39 (92.9%)  < 0.001 * 
 Cholecalciferol (VitD3) 45 (17.0%)  3 (10.0%)  42 (100%)  < 0.001 * 
 Ergocalciferol (VitD2) 30 (11.3%)  30 (100%)  0  < 0.001 * 
 Multivitamin 72 (27.2%)  10 (33.3%)  21 (50.0%)  0.159  
 Calcium with VitD 22 (8.3%)  2 (6.7%)  8 (19.0%)  0.134  
          
* = significant at the p < 0.05 level        
BMI = body mass index, GBP = gastric bypass, VSG = vertical sleeve gastrectomy, AGB = adjustable 






This pre-operative bariatric surgery cohort is more predominantly female (83.0%) than reports 
of many post-operative cohorts including our own center. Within that last 6 months, 75% of the 
bariatric surgeries performed at our center have been in women. This may be due to attrition of 
female patients prior to surgery. The median age of patients undergoing bariatric surgery at our 
center during this same 6 month time period was 45 years, which is very similar to the median 
age in this pre-operative cohort (43 ± 13 years). Median BMI (46.3 ± 10.5 kg/m2) in these pre-
operative patients is also in line with patients who undergo surgery at our center (46 kg/m2). 
While the distribution of race is not dissimilar to what we typically observe at our center, there 
are fewer whites with this cohort being about 50% white and our post-operative cases being 
about 65% white. This may mean that some black candidates do not make it through the 
process to undergo bariatric surgery. 
Most procedures were slated to be performed laparoscopicaly, 78.1%. The majority of patients 
were interested in undergoing the VSG (55.8%), the vast majority of which would likely be 
performed laparoscopicaly (91.2%). In comparison, only 58.3% of all GBPs were intended to be 
performed laparoscopicaly. VSG shows the highest frequency of laparoscopy in any procedure 
when excluding the lone AGB, which is expected to be laparoscopic. VSG is predominant in this 
pre-operative cohort (55.8% of all procedures), but not as predominant as we would expect for 
our center. Over 70% of all procedures in the last 6 months at our center have been VSG. This 
could be due to attrition of patients seeking GBP or perhaps these patients decide to undergo 
VSG instead. More surgeries in the past 6 months were actually performed laparoscopicaly than 
this pre-operative cohort would indicate (96% vs.65.2% in VSG and 86% vs. 27.0% in GBP). This 
may also be due to attrition, perhaps in those patients who are told they are only candidates for 
traditional open surgery. 
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Despite the relatively similar proportions of whites and blacks in this cohort as a whole, VSG and 
laparoscopy represented significantly more white candidates than black (55.1% vs. 44.9%, 
p=0.016 and 54.4% vs. 46.0%, p=.0192 respectively). The difference in procedure may be due to 
a larger proportion of undecided candidates, which was border-line significant (10.2% vs. 6.2%, 
p=0.068). As for fewer black candidates undergoing laparoscopy, one would anticipate this to be 
due to risk factors associated with the need for traditional open surgery, such as higher BMI and 
scarring from previous surgery (preventing placement of the ports). While the median BMI is 
higher in black candidates, this difference is not statistically significant (47.3 ± 11.0 kg/m2 vs. 
46.0 ± 9.6 kg/m2, p=0.301). Perhaps these patients have had previous surgeries, which require 
the bariatric procedure to be performed in the traditional open approach. 
The median serum 25(OH)D concentration (VitD status) in this bariatric pre-operative cohort  is 
21.5 ± 15.3 ng/ml (53.8 ± 38. 2 nmol). VitD status did not vary by sex or race. To further explore 
differences by race, we compared whites to blacks, but found the relationship was still non-
significantly different (Δ=6.8 ng/ml, p=0.141). Despite darker skin pigmentation (higher 
concentration of melanin) being a risk factor for VitD deficiency, there was no difference by race 
or when comparing blacks to whites in the availability of VitD status test, whether testing had 
been ordered, history of VitD deficiency, treatment for VitD deficiency, or use of a multivitamin 
or calcium with VitD. There was also no relationship with these factors and sex with the 
exception of multivitamin intake. Women were border-line significantly more likely to take a 
multivitamin (29.6% vs. 15.6%, p=0.055). 
We attempted to determine factors that may lead to a candidate being tested for VitD 
deficiency by their PCP, (  
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Table 25). There were no differences in age, sex, BMI, procedure, approach or race. The 
proportion of whites versus blacks who were tested was also comparable (17.8% vs. 19.5%, 
p=0.500). One might expect a higher proportion of blacks to have their VitD status tested given 
the additional risk factor (beyond obesity), but this was not seen in this cohort. Perhaps this is 
an issue of access to care, but it is also possible that more education is necessary for PCPs 
relating to the need for VitD testing in this population, especially in patients with multiple risk 
factors (e.g. obesity and high melanin concentration). Where we did see distinction in the 
likelihood of testing was with history and treatment of VitD deficiency. Those who had VitD 
status testing in their medical record at our center were much more likely to have a history of 
VitD deficiency (65.3% vs. 12.2%, p<0.001). This may be because those with a history of VitD 
deficiency are more likely to undergo periodic VitD testing. Candidates who were tested were 
also more likely to be on high dose VitD therapy (26.5% vs. 8.3%, p<0.001) and VitD2 (24.5% vs. 
8.3%, p=0.001); another indicator of medical management of VitD deficiency. Candidates for 
whom we had 25(OH)D were also more likely to be taking VitD3 (26.5% vs. 14.8%, p=0.049). This 
may mean that their physicians have transitioned them from repletion therapy (high dose VitD2) 
to maintenance therapy (daily VitD3). 
VitD status was tested in 18.5% of this cohort, and 34.8% were VitD deficient (< 20 ng/ml, 50 
nmol/L) while 71.7% were VitD insufficient (< 30 ng/ml, 75 nmol/L), see Chapter 4. Previous 
studies in bariatric candidates have reported much higher rates of VitD deficiency and 
insufficiency. In a previous study at our center, we found 71.4% of our pre-operative patients 
were VitD deficient and 92.9% met clinical criteria for treatment (< 32 ng/ml, 80 nmol/L), see 
Chapter 4. This means a significant proportion of those who were not tested are likely to be VitD 
deficient and/or insufficient. One would anticipate that patients undergoing a malabsorptive 
procedure like GBP might be more likely to be tested for deficiency in fat soluble vitamins, a side 
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effect of the procedure, but that is not clear from these results. VitD status was tested in 20.8% 
of candidates for GBP and 18.2% in candidates for VSG, not a statistically significant difference 
(p=0.292). 
In 87.1% of all cases of high dose, medically monitored, VitD supplementation in this cohort, 
VitD2 was administered instead of VitD3, p < 0.001, likely due to the fact that most 
pharmaceutical preparations in the US are VitD2. Furthermore, there was a conception that 
VitD2 is safer than VitD3 and many physicians were trained to administer VitD2 in high doses. The 
opposite is true of daily VitD supplementation in this cohort. VitD3 was used in 95.1% of all cases 
of daily VitD therapy, p < 0.001. Daily VitD supplementation was positively associated with 
intake of a multivitamin (51.1% vs. 22.3% in non-daily users, p<0.001) and calcium with VitD 
(20.0% vs. 5.9% in non-daily users, p=0.002). A similar link is observed between those taking a 
multivitamin (30.6% vs. 10.4%, p < 0.001) and calcium with VitD (36.4% vs. 14.0%, p=0.006) with 
daily VitD therapy. 
Whites were more likely to use VitD daily instead of high dose VitD therapy (58.5% vs. 49.2%, 
p=0.032), while blacks were more likely to be prescribed high dose VitD therapy rather than 
using VitD daily (51.6% vs. 39.0%, p=0.005). This racial difference may be explained if blacks are 
less likely to take VitD supplementation unless found to be VitD deficient, in which case they are 
likely to be prescribed high dose VitD therapy. In fact, those on high dose VitD therapy were 
more likely to have a history of VitD deficiency (83.9% vs. 26.8%, p<0.001). It is also possible that 
white candidates may have a larger proportion of individuals who are more proactive with their 
health and thus take daily VitD to prevent deficiency. 
Candidates hoping to undergo the VSG procedure were more likely to take VitD daily rather than 
high dose VitD therapy (56.1% vs. 45.2%, p=0.008) and to be taking VitD3 versus VitD2 (57.1% vs. 
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40.0%, p<0.001), likely because over-the-counter formulations are typically VitD3. Since VSG is 
not a malabsorptive procedure, the risk of VitD deficiency after surgery is less than with GBP, 
which may mean that PCPs are less likely to treat their patients with medically monitored high 
dose VitD therapy if they are VSG candidates instead of GBP candidates.  
LIMITATIONS 
The data for this study were gathered from our electronic medical record (EMR). There is the 
possibility of human error in terms of data entry. It is also possible that there is a lag in updates 
appearing in the EMR. This lag may be due to data transfer from one program to another or to 
delay from the time of hard copy receipt to entry into the EMR. This also affects clinical care. 
There is a potential for reporting bias in our patients. If a patient has not seen the surgeon or 
nutritionist, they may not fully comprehend the importance of reporting all supplements and 
any nutritional testing. However, if we were to implement a pre-operative treatment program, 
we would face similar data limitations. 
STRENGTHS 
We have analyzed the EMR of 265 consecutive patients with appointments at our center, an 
academic Center of Excellence, over a period of 3 months. The large sample size as well as the 
sampling technique strengthens the validity of our analysis. We have established a baseline to 
assess future interventions at our center. Our results are also generalizable to most academic 




We found testing for VitD status to be lower than would be clinically indicated in pre-bariatric 
surgery patients. While all patients in this cohort have obesity (BMI 46.3 ± 10.5 kg/m2), which is 
a risk factor for VitD deficiency, at least 44.5% have more than one risk factor, since these 
patients have high melanin concentration (darker skin pigmentation). Despite this, only 18.5% of 
bariatric candidates had serum 25(OH)D concentration on file in their medical records at our 
center. Of that group, 34.8% were VitD deficient (< 20 ng/ml, 50 nmol/L) and 71.7% were VitD 
insufficient (< 30 ng/ml, 75 nmol/L). Much higher rates of VitD deficiency and insufficiency have 
been reported for pre-operative bariatric surgery patients including a previous study at our 
center where we found VitD deficiency in 71.4% of patients prior to surgery. A significant 
proportion of bariatric surgery candidates have not had their VitD status tested but yet are likely 
to be VitD deficient and/or insufficient. The consequences of this deficiency on surgical and 
clinical outcomes have not been fully elucidated. Furthermore, those patients who are being 
treated for VitD deficiency are not being treated with the most effective formulation, VitD3 
(cholecalciferol). Since pharmaceutical preparations are largely VitD2 (ergocalciferol) the 
likelihood of a patient being prescribed VitD2 over VitD3 is great; however, education, 
particularly targeting PCPs, could overcome this and lead to improved treatment of VitD 




CHAPTER 6: FUTURE PROJECTS 
We have many future projects on the horizon. Clinically, we would like to improve the 
proportion of our patients undergoing testing for serum 25(OH)D concentration. This 
information will be crucial for The VISTA trial: The effect of VItamin D supplementation on 
nutritional STatus and Adverse outcomes in bariatric surgery. The VISTA trial is a randomized, 
double-blinded controlled trial that has been approved by the John Hopkins Institutional Review 
Board (IRB00044789). We are actively recruiting participants into this study. 
An additional study which is currently underway involves a collaboration between the Wong 
Laboratory in the Johns Hopkins Center for Metabolism and Obesity Research and the Johns 
Hopkins Center for Bariatric Surgery: Altered Vitamin D and Adiposity in Obesity. We have 
developed a translational research project to study the relationship between vitamin D status 
and adipokines in human adipose tissue in the abnormal metabolic state of obesity. We 
hypothesize that vitamin D status and adipokine expression varies depending on body weight, 




THE VISTA TRIAL: THE EFFECT OF VITAMIN D SUPPLEMENTATION ON NUTRITIONAL 
STATUS AND ADVERSE OUTCOMES IN BARIATRIC SURGERY 
OBJECTIVES 
Primary Objective: To determine whether 10,000 IU of vitamin D3 (cholecalciferol) daily for 30 
days prior to bariatric surgery (RYGB or VSG) will significantly increase the vitamin D status, as 
measured by serum 25(OH)D concentration. 
Secondary Objective: To determine whether 10,000 IU of vitamin D3 (cholecalciferol) daily for 
30 days prior to bariatric surgery (RYGB or VSG) leads to decreased risk of adverse surgical 
outcomes. 
BACKGROUND 
An estimated 2 in 3 American adults are either overweight (BMI 25-29.9 kg/m2) or obese (BMI 
30-39.9 kg/m2). The prevalence of obesity, class 3 obesity (BMI 40-49.9 kg/m2), and even class 4 
(BMI 50-59.9 kg/m2) and 5 (BMI ≥ 60 kg/m2) obesity are increasing 217;218. Obesity is a leading 
contributor to global mortality and contributes to the burden of disease associated with 
diabetes, cardiovascular disease, musculoskeletal disorders such as osteoarthritis, and some 
cancers 104. Morbid obesity reduces life expectancy by 8 to 10 years, similar to the effect of 
being a regular cigarette smoker 219. 
Several studies have demonstrated that most obese adults are vitamin D (VitD) insufficient (<75 
nmol/L, 30 ng/ml) or deficient (<50 nmol/L, 20 ng/ml). The inverse relationship between body 
mass index (BMI) or body fat mass and VitD status is hypothesized to be due to sequestration of 
VitD by adipose tissue, reducing the bioavailability of VitD 220. The classical role of VitD is in the 
maintenance of bone calcification, but more recent research has elucidated a more varied role 
for this hormone. Lack of VitD has been associated with increased susceptibility to infection, 
autoimmunity, cancer, and chronic disease 221. 
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Bariatric surgery is currently the most successful means of long-term weight loss. Since 
deficiency in fat-soluble vitamins, such as VitD, is considered a metabolic complication of 
bariatric surgery, determining the VitD status of these individuals and perhaps correcting it prior 
to surgery may prove greatly beneficial. Potential complications relating to VitD insufficiency 
and deficiency include adverse surgical outcomes such as improper wound healing, infection of 
the surgical incision, and atrial fibrillation. Since the indications for bariatric surgery are obesity 
and obesity-related comorbidities, bariatric surgery patients are at an increased risk of having an 
adverse surgical outcome. 
The Johns Hopkins Center for Bariatric Surgery (JHCBS) is designated as a Center of Excellence by 
the American College of Surgeons. To comply with this designation, our center must maintain a 
certain standard of care (SoC) and minimize complication rates. Given the potential relationship 
between VitD status and adverse surgical outcomes, we are currently reviewing pre-operative 
VitD status (serum 25(OH)D concentration) collected as routine SoC and investigating the 
relationship with surgical outcomes under an Institutional Review Board (IRB) approved protocol 
(NA_00087502). Our findings reveal that most of our patients are VitD insufficient and deficient 
pre-operatively. To date, there is no standard regarding treating these deficiencies pre-
operatively and as such our center does not intervene prior to surgery. A randomized, double-
blinded, placebo-controlled pilot trial is needed to assess the causality of the relationship 
between pre-operative VitD status and adverse surgical outcomes in the bariatric surgical 
patient. 
We plan to identify new patients approved for bariatric surgery at the JHCBS. These patients will 
be randomized consecutively in a 1:1 ratio to either 30 days of 10,000 International Units (IU) of 
VitD3 plus SoC or 30 days of placebo plus SoC immediately prior to surgery. We will monitor 
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these patients for any adverse surgical outcomes, including wound infection, dehiscence, and 
prolonged length of hospital stay. We will also monitor their long-term clinical outcomes such as 
malnutrition, weight loss, and resolution of comorbidities at their routine clinic care visit: 2 
weeks, 6 weeks, 3 months, 6 months, and 12 months post-operatively. At these visits the 
patients are assessed for obesity related comorbidities, wound healing, weight loss, nutritional 
status, and other key markers of health, such as vital signs. 
We aim to determine if 10,000 IU of VitD3 daily for 30 days prior to bariatric surgery (Roux-en Y 
Gastric Bypass (RYGB) or Vertical Sleeve Gastrectomy (VSG)) will significantly increase the VitD 
status (serum 25(OH)D concentration) and whether the associated change in VitD status leads to 
decrease risk of adverse surgical outcomes and/or improved clinical outcomes. 
STUDY DESIGN  
All patients who present to the JHCBS have pre-operative blood work, which includes VitD status 
(serum 25(OH)D concentration), which is used to inform the treatment of each patient with VitD 
supplementation post-operatively. We propose to screen this data in order to identify patients 
who have insufficient VitD stores (< 75 nmol/L, 30 ng/ml), and thus may be at risk for adverse 
surgical outcomes. Once these patients are identified, we will approach them to participate in 
this research study (see Figure 24). If the patient chooses to participate, they will receive a 30 
day supply of either placebo or 10,000 IU of VitD3 for research purposes in addition to receiving 
standard of care (SoC). We will ask that they take one of these supplements (placebo or VitD) 
daily with their largest meal of the day until their surgery. On the day of their surgery, we will 
administer a questionnaire designed to assess compliance (what dose was actually delivered) 




VISTA Trial Diagram 
 
FIGURE 24 DIAGRAM OF THE VISTA TRIAL 
 
After initiating informed consent and obtaining written consent, consecutive patients will be 
randomly assigned in a 1:1 ratio to either the treatment arm (SoC plus 10,000 IU of VitD3) or the 
control arm (SOC  plus placebo). Randomization will be performed by the Johns Hopkins 
Bayview Research Pharmacy. Using a computer-generated randomization scheme, uniform 
distribution will be utilized. Variables will be drawn with equal probability from all values in the 
range of 0 to 1. Each block of 4 will contain equal numbers of treatment (VitD) and placebo 
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assignments. Each successive study participant will be randomized by selecting the next 
available treatment assignment in the random code. The research study team will be blinded to 
the contents of the kits, knowing only for which study identification number they are intended. 
The research study team will be given kits containing either VitD (treatment) or placebo 
(control) to give to the study participants. The placebo—produced by the Research Pharmacy—
will consist of gummy buttons in blister packs. This preparation will appear very similar to the 
VitD supplements in the treatment arm. 
The VitD supplements will be provided by Bariatric Advantage at no cost. This product is a 
chewable gel that delivers 10,000 IU of VitD3 (cholecalciferol) per dose (1 gel). The patented gel-
emulsion technology is designed to support greater bioavailability. Each gel contains 5 calories 
from 0.5 g of sugar alcohol. They also contain a natural lemon flavor. The packaging is specially 
engineered to protect each individual gel from light and oxygen to maintain optimal stability 
(blister packs). Our center recommends this product to our bariatric patients for VitD 
supplementation post-operatively. 
Both the gummy buttons and the VitD gels are not vegetarian. They are made of beef gelatin 
(not encapsulated). We will inform all subjects that beef gelatin is used in these supplements 
during the informed consent process. 
Subjects will be provided a 30 day supply of either the Bariatric Advantage VitD chewable gels or 
placebo (gummy buttons in blister pack) about 1 month from surgery. They will be instructed to 
take 1 gel each day with their largest meal. The fat typically present in the largest meal of the 
day will aid in the absorption of the VitD, which is fat soluble, if the patient has been 
randomized to the VitD arm. 
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On the day of surgery, we will ask them to complete the Post-Supplementation Survey to assess 
their compliance and experience taking the supplement. As we do in our other approved 
protocol, we will monitor these patients for any adverse surgical outcomes (wound infection, 
separation, dehiscence, and prolonged length of hospital stay) in addition to their long-term 
clinical outcomes such as malnutrition, weight loss, and resolution of comorbidities. 
Our center participates in the American College of Surgeons Surgical Quality Improvement 
Program (ACS NSQIP®). ACS NSQIP® requires that we report mortality, surgical site infection, 
and other adverse events for 30 days following surgery. The routine SoC at our center is to see 
patients at 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and annually thereafter, as 
required by the ACS to maintain our Center of Excellence designation. We will monitor the 
outcomes of these patients through the 12 month visit. This will include information about 
adverse events, wound healing, weight loss, vital signs, nutritional status, resolution of 
comorbidities, etc.  
STUDY DURATION AND NUMBER OF STUDY VISITS 
Our center performs 380 surgeries each year or roughly 7 surgeries per week. Preliminary data 
shows that 71% of our patients are VitD deficient (< 50nmol/L, 20 ng/ml) and 93% are VitD 
insufficient (< 75 nmol/L, 30 ng/ml) prior to surgery. We will likely have about 6 surgeries per 
week performed on patients with VitD insufficiency, making them potentially eligible to 
participate in this study. If we expect 75% to be willing to participate (based on experience with 
our previous studies), we should be able to recruit 4 patients per week. At this rate we should 
be able to recruit all 70 participants necessary in about 18 weeks. Thus, we expect this study to 
actively recruit participants for approximately 5 months. Following each patient requires an 
additional year, so we anticipate that this study will last for 1.5 years. 
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We will see each participant for 2 study visits. The first visit will occur at their routine pre-
operative clinic visit, at which we will provide them with their 30 day supply of supplement 
(placebo or VitD at no cost) and a parking pass. The second visit will occur on the day of their 
surgery in the Ambulatory Surgery Unit. At this final visit, we will administer the questionnaire 
on compliance and satisfaction and provide them with an additional parking pass. We will not 
interact with the participants after their surgery, but instead will monitor them through the 
clinical system. 
BLINDING 
This is a double-blinded, placebo controlled pilot study. The blinding prevents bias from the 
investigator or the participant, and the placebo allows us to account for the placebo effect.  
Blinding, randomization and preparation of the study drug will be carried out at the Johns 
Hopkins Bayview Inpatient Research Pharmacy. 
JUSTIFICATION FOR INCLUSION OF A PLACEBO GROUP 
At present, the routine SoC at our center is not to administer VitD supplements prior to surgery 
regardless of nutritional status (serum 25(OH)D concentration). Supplementation currently only 
occurs after surgery, when patients are instructed to take 3,000 IU of VitD3 daily in addition to a 
calcium supplement that must contain VitD. This means each patient should be taking up to 
4,200 IU of VitD3 daily. They are then monitored for their VitD status at 3, 6, and 12 months and 
annually thereafter or more frequently if clinically indicated. High dose treatment is frequently 
administered post-operatively in addition to daily supplementation. This high dose treatment 
ranges from 50,000 IU of VitD weekly to twice weekly for 8 to 16 weeks. 
The placebo group in this study, thus, receives the routine SoC at our center—what they would 
receive if they decline to participate in this study. 
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DEFINITION OF TREATMENT FAILURE OR PARTICIPANT REMOVAL CRITERIA 
We will perform an intention to treat analysis, but will also assess compliance via a 
questionnaire—the Post-Supplementation Survey. If a participant took their supplement 
“Occasionally (10-15 of 30)”, “Rarely (< 10 of 30)”, or “Never (0 of 30);” we will remove them for 
the purposes of a subset analysis. 
INCLUSION/EXCLUSION CRITERIA 
Inclusion Criteria: 
 Patients approved for and undergoing clinically indicated bariatric surgery –Roux-en-Y 
Gastric Bypass (RYGBP) or Vertical Sleeve Gastrectomy (VSG) 
 18 to 64 years of age 
 BMI of 35 to 49.9 kg/m2 
 VitD insufficient pre-operatively: serum 25(OH)D concentration < 75 nmol/L or 30 ng/ml 
Exclusion Criteria: 
 Any patient who does not want to participate in the study 
 Any patient who has dietary restrictions/proscriptions prohibiting ingestion of beef 
gelatin 
 Expected poor compliance with the medical regimen 
 Any active medical conditions that could, in the opinion of the investigators, jeopardize 
the safety of the subject or the integrity of the study 
 The elective bariatric surgery is cancelled prior to incision by a surgeon for any reason 
 Pregnancy: The routine standard of care is to determine whether a female patient is 
pregnant either by history and/or urinary pregnancy test on the day of surgery. No 
additional testing specifically for this study is planned beyond the standard of care 
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RATIONALE FOR CHOOSING THE DRUG AND DOSE 
In order to improve VitD status (raise serum 25(OH)D concentrations) in patients, 
supplementation with cholecalciferol (VitD3) is recommended. While supplementation with the 
plant version of VitD, ergocalciferol (VitD2), has been used in the past it is becoming clear that 
there are advantages to VitD3 and that it is more effective than VitD2 at remedying deficiency 
(repletion). VitD3 is safe even at very high doses such as 600,000 IU annually or 40,000 IU daily. 
While large monthly (100,000 IU) or weekly dosing (50,000 IU) has been used to correct VitD 
deficiency the pharmacokinetics of VitD favor daily dosing, as declining 25(OH)D (regardless of 
total amount) leads to declining activation into 1,25(OH)2D. A more appropriate dosage would 
thus be 7,000 to 10,000 IU daily, which is why we have selected a 10,000 IU dose of VitD3 to be 
taken daily. The Institute of Medicine has deemed VitD to be safe in doses up to 10,000 IU per 
day for prolonged periods of time in the general population. Since this population will be VitD 
insufficient, any potential risks of VitD supplementation will be greatly diminished and certainly 
outweighed by the potential benefits. In addition, daily supplement intake creates a habit, which 
increases the likelihood of compliance, assuring dosage delivery. 
STUDY STATISTICS 
Primary outcome variable: VitD status as measured by serum 25(OH)D concentration. 
Secondary outcome variables: 
 Adverse surgical outcomes: surgical site infection, wound separation and dehiscence, 
anastomotic leak, prolonged length of hospital stay (> 3 days), re-admittance to the 
hospital within 30 days post-operatively. 
 Clinical outcomes: wound healing, weight loss, nutritional status, resolution of 
comorbidities, and other key markers of health, such as vital signs (fever, blood 




We expect the average serum 25(OH)D concentration (VitD status) in our patients to be 37.5 
nmol/L or 15.0 ng/ml from preliminary data. We hope to raise 25(OH)D in the VitD arm to above 
50 nmol/L or 20 ng/ml with only 35% of participants remaining VitD deficient after treatment—a 
roughly 50% decrease. To detect this difference in the proportion of patients who are VitD 
deficient (71.4% versus 35%), we will need to recruit 28 patients for each group for a total of 56. 
Given a 20% loss to follow up we will need to recruit 34 patients for each group (68 total). We 
will round that number up and recruit 35 participants per group for a grand total of 70 
participants in this study. 
We will perform an intention to treat analysis, but will also assess compliance via a 
questionnaire—the Post-Supplementation Survey. If a participant took their supplement 
“Occasionally (10-15 of 30)”, “Rarely (< 10 of 30)”, or “Never (0 of 30);” we will remove them for 
the purposes of a subset analysis. We will also perform analysis stratified by procedure type to 
assess for potential differences between the malabsorptive RYGB compared to the mildly 
malabsorptive VSG. 
VitD status is a continuous variable, so for most analysis we will use it as such. However, it may 
also be divided into biologically or population relevant categories. To classify VitD deficiency, we 
will use guidelines from the Institute of Medicine, < 50 nmol/L or 20 ng/mL. Additionally, we will 
use 75 nmol/L or 30 ng/mL as the cut-off to determine sufficiency, which may be necessary for 
the immune bolstering effects of VitD. Within our cohort, it may also be informative to divide 
VitD status by tertiles or quartiles as well as to focus on the highest and lowest VitD status of 




EARLY STOPPING RULES 
If we find that 10,000 IU of VitD3 daily does not increase serum 25(OH)D concentration (VitD 
status), in the VitD arm during our interim analysis, we will discontinue this version of the study 
and re-design it with a higher dose, using this data to inform that higher dose. We will perform 




The Institute of Medicine has deemed VitD to be safe in doses up to 10,000 IU per day for 
prolonged periods of time in the general population. Since this population will be VitD 
insufficient (< 75 nmol/L, 30ng/ml), any potential risks of VitD supplementation will be greatly 
diminished and certainly outweighed by the potential benefits in this population. Toxicity is not 
possible in this population of VitD insufficient individuals due to the dose (10,000 IU of VitD3 
daily) and duration (30 days) of supplementation. The serum 25(OH)D concentrations in these 
patients would need to be increased an order of magnitude in order to become at risk of VitD 
toxicity (> 500 nmol/L, 200 ng/ml). The potential risks of excessive VitD are primarily 
hypercalcemia and hypercalciuria. These are uncommon and have been found at similar rates in 
the control and treatment groups of numerous other VitD supplementation studies. 
STEPS TAKEN TO MINIMIZE THE RISKS 
We have chosen a dose (10,000 IU of VitD3 daily) at which we should see a profound 
improvement in VitD status with minimal risk. In addition, the short duration of 
supplementation (30 days) will limit the possibility of side effects, though rare even at higher 
doses and durations or in the general population. It is possible that this dose/duration 
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combination will not be sufficient to replete this population, which is why we will perform an 
interim analysis to assess the efficacy of this supplementation in this study population. 
PLAN FOR REPORTING UNANTICIPATED PROBLEMS OR STUDY DEVIATIONS  
All events will be reported to the Johns Hopkins Medicine (JHM) IRB as required by the JHM IRB 
reporting guidelines posted on the JHM IRB website. 
LEGAL RISKS SUCH AS THE RISKS THAT WOULD BE ASSOCIATED WITH BREACH OF CONFIDENTIALITY 
There should be no legal risks by participating in this study beyond those associated with routine 
care. 
FINANCIAL RISKS TO THE PARTICIPANTS 
There should be no financial risks by participating in this study beyond those associated with 
routine care. 
BENEFITS 
No direct benefits for study subjects, but the results of this work may improve care of future 
bariatric patients. 
PAYMENT AND REMUNERATION 
Since there are no extra visits and little extra time required of the participants in this study, we 
will not compensate them monetarily. Participants will receive 2 parking passes (1 in clinic when 
they receive their supplements and 1 on the day of surgery when they complete the 
questionnaire) as compensation for their time and efforts. 
COSTS 
There are no costs to participate in this study. Participants (or their insurance) are responsible 
for paying the costs of routine standard of care and follow-up clinical examination visits 
associated with bariatric surgery. 
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ALTERED VITAMIN D AND ADIPOSITY IN OBESITY 
SPECIFIC AIMS  
An estimated two-thirds of American adults are either overweight or obese, and the prevalence 
of obesity is increasing.216 Several studies have demonstrated that most obese adults are 
vitamin D (VitD) insufficient (<80 nmol/L, 32 ng/L) or deficient (<50 nmolL, 20 ng/L).104;147;150;210  
The inverse relationship between BMI or body fat mass and VitD status 147;151;210 is hypothesized 
to be due to sequestration of VitD by adipose tissue, reducing the bioavailability of VitD.217;218 
Adipose tissue is now recognized as a metabolically active endocrine organ. Adipose tissue 
expresses the VitD receptor (VDR) and activates the circulating form of VitD, 25(OH)D, into the 
active form, 1,25(OH)D, which binds to the VDR 147.  Adipose tissue may both regulate and be 
regulated by VitD 217. Adipose tissue as an endocrine organ also secretes adipokines, which are 
proteins involved in inflammation, metabolism and energy homeostasis.  Adiponectin is an 
adipokine exclusively secreted by adipose tissue that modulates glucose metabolism and fatty 
acid oxidation, with an inverse correlation with body weight and metabolic syndromes.  The 
C1q/TNF-related proteins (CTRP) family of proteins are adiponectin paralogs that play an 
important role in regulating glucose and lipid metabolism.  Understanding the link between VitD 
status and energy homeostasis may be one of the vital links in ameliorating the obesity 
epidemic.  
In a strong collaboration between the Wong Laboratory in the Johns Hopkins Center for 
Metabolism and Obesity Research and the Johns Hopkins Center for Bariatric Surgery, we have 
developed a translational research project to study the relationship between VitD status and 
adipokines in human adipose tissue in the abnormal metabolic state of obesity. We hypothesize 
that vitamin D status and adipokine expression varies depending on body weight, and aim to 
study this in the morbidly obese patient pre- and post-bariatric surgery. 
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Specifically, we aim: 
1. To determine vitamin D status—serum 25(OH)D concentration—pre- and post-bariatric 
surgery (immediately prior to surgery and 3, 6, and 12 months after surgery). 
2. To evaluate circulating adipokines pre- and post-bariatric surgery (immediately prior to 
surgery and 3, 6, and 12 months after surgery). 
3. To assess vitamin D metabolites and receptor expression and adipokines in obese 
adipose tissue and compare to normal weight control tissue (healthy controls). 
4. To elucidate the relationship between vitamin D and adipokines, and their impact on 
metabolism in the obese patient. 
BACKGROUND 
VITAMIN D AND OBESITY 
According to the National Health and Nutrition Examination Survey (NHANES) 2001-2004, 1 in 3 
Americans have deficient VitD stores (<50 nmol/L, 20 ng/ml) and 3 in 4 have sub-optimal or 
insufficient VitD stores (<75 nmol/L, 30 ng/ml) 154.  Risk factors for VitD deficiency include living 
in the northern latitudes, greater melanin concentration in the skin, sun avoidance practices 
such as daily sunscreen use or veiling, working the night shift, absence of fatty fish intake, liver 
or kidney disease, exclusive breast feeding for infants, inability to digest/absorb fats (i.e. after 
gastric bypass), polymorphisms, as well as obesity.  A large study by Vimaleswaran et al. found a 
10% increase in body mass index (BMI) was correlated with a 4% decrease in VitD status 151.  
This decrease is most likely due to sequestration of VitD in the fat, leading to lower VitD 
bioavailability. 
The classical role of VitD is in the maintenance of bone calcification, but more recent research 
has elucidated a more varied role for this hormone.  Lack of VitD has been associated with 
increased susceptibility to infection, autoimmunity, cancer, and chronic disease 222.  VitD plays a 
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role in regulating the inflammation that contributes to many chronic diseases, and has shown 
the potential to prevent diseases such as type 2 diabetes mellitus 153;154.  Obesity is also 
associated with chronic inflammation and an increased risk of chronic diseases.  Hence, obese 
individuals with insufficient stores of VitD may have extraordinary risk of chronic inflammation 
and associated comorbidities. 
VITAMIN D AND BARIATRIC SURGERY 
Currently, sustained long-term weight loss is most successfully obtained with bariatric surgery.  
During bariatric surgery, the digestive tract is restricted in size with particular focus on the 
stomach, leading to weight loss.  Reports suggest that 40-68.1% of bariatric surgery patients are 
VitD deficient 196.  Since deficiency in fat-soluble vitamins, such as VitD, is considered a 
metabolic complication of bariatric surgery, determining the VitD status of these individuals and 
perhaps correcting it prior to surgery may prove greatly beneficial 196.   Fish et al. showed that 
VitD insufficiency 
(<75 nmol/L, 30 
ng/L) persisted in 
gastric bypass 




prior to surgery 
(50,000 IU VitD3 3 
times per week 
for 1 month)  and 
FIGURE 25 SERUM VITAMIN D CONCENTRATION RELATIVE TO OBESITY 
GASTRIC BYPASS SURGERY.  FIGURE ADAPTED FROM COMPHER, BADELLINO, 
AND BOULLATA.   
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maintenance supplementation for life, with a daily dose of 1200 IU 25(OH)D3 209.  Interestingly, 
there appears to be an increase in serum 25(OH)D in this cohort immediately following surgery 
and then a slow decline in status likely due to the release of VitD from fat sequestration during 
weight loss 209.  Compher, Badellino, and Boullata conducted a review in 2008 and produced a 
graph showing serum 25(OH)D concentration over time following bariatric surgery, which we 
have altered to produce Figure 25223.  Most striking about Figure 25 is that VitD deficiency 
lingers uncorrected in most of these patients for years. 
Potential complications relating to VitD insufficiency and deficiency include adverse surgical 
outcomes such as improper wound healing 156, infection of the surgical incision 130;157, and atrial 
fibrillation 130. Since the indications for bariatric surgery are obesity and obesity-related 
comorbidities, bariatric surgery patients are at an increased risk of having an adverse surgical 
outcome.  VitD deficiency is likely a risk factor that can be easily remedied prior to surgery and 
therefore may prevent such adverse surgical outcomes following bariatric surgery. 
VITAMIN D AND ADIPOSE TISSUE: THE ROLE OF ADIPOKINES 
Adipose tissue is one of the extraskeletal targets of VitD. The effects of VitD on adipogenesis in 
vitro are not completely clear, as 1,25(OH)D inhibits adipogenesis in mouse preadipocytes, while it 
stimulates adipogenesis in human adipocytes in vitro 224;225. There is likely a role for the VDR in the 
regulation of adipogenesis and energy metabolism as VDR knockout mice are lean and resistant to 
developing obesity on a high fat diet 226. Adipose tissue metabolizes VitD, but this function is likely 
altered in obesity and with weight loss.   
Adipose tissue derived hormones, or adipokines, and VitD both play a role in energy homeostasis.   
In mouse models, 1,25(OH)D stimulates adipose leptin production in a VDR dependent manner 227, 
but the relationship between VitD and leptin has not been explored in humans and human 
adipose tissue. Further, it has been suggested by a proteomic approach that adiponectin links VitD 
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deficiency to obesity 228.  The Wong Laboratory focuses on a novel family of adipokines, termed 
CTRPs, that have anti-inflammatory properties and are involved with both glucose and lipid 
metabolism 229.  We hope to expand the investigation of different adipokines and their 
relationship to VitD in humans and human adipose tissue.  
PRELIMINARY DATA 
Recently, the Johns Hopkins Center for Bariatric Surgery began assessing nutritional status in 
their pre-operative patients as standard of care.  Preliminary data shows that 98.3% of patients 
are VitD insufficient (<80 nmol/L, 32 ng/ml) and 72.4% are deficient (<50nmol/L, 20 ng/ml).  
Insufficiency and deficiency are most common in non-Caucasian patients (p=0.015).  We have 
also found significant pair-wise correlations between VitD status and age (p<0.001) and BMI 
(p=0.003). 
RESEARCH DESIGN AND METHODS 
We are conducting a translational research study as a collaboration between the Wong 
Laboratory in the Center for Metabolism and Obesity Research and the Center for Bariatric 
Surgery at the Bayview Medical Center (PI: Kimberley E. Steele, MD, PhD, FACS).  Obese study 
patients undergoing bariatric surgery will be recruited to participate in this study (Figure 26). 
Blood and adipose tissue samples will be obtained, with the following aims: 
1. To determine differences in vitamin D status in obese patients prior to and after 
undergoing bariatric surgery. 
2. To assess correlations between vitamin D status, circulating adipokines, and variables 
such as weight, weight loss, insulin, glucose, hemoglobin A1C, cholesterol, liver function 
studies (LFTs), and parathyroid hormone. 
3. To compare expression of the vitamin D receptor and enzyme function in obese adipose 
tissue and compare this to fat tissue from normal weight healthy controls. 
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4. To elucidate the relationship between vitamin D status and adipose tissue expression of 




FIGURE 26 ASSOCAITION OF VITAMIN D STATUS AND ADIPOSE TISSUE FUNCTION IN OBESE PATIENTS 
UNDERGOING BARIATRIC SURGERY 
 
PATIENT RECRUITMENT AND FOLLOW-UP 
We will recruit 60 obese patients who are scheduled to undergo bariatric surgery at the Bayview 
Medical Center.  Obese study patients (BMI>40) will be recruited at their pre-operative visit 
where demographic information, history, height and weight measurements are obtained as 
routine care.  Pre-operative blood work (including LFTs, HbgA1C, insulin, glucose, cholesterol 
panel, VitD and PTH levels) and an additional blood sample will be obtained for ELISA testing of 
adipokines in our research laboratory.  During surgery, visceral (omental) and subcutaneous 
adipose tissue will be procured.  Obese patients will be followed at their 3, 6, and 12 month 
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post-surgical follow-up visits, where repeat blood work is obtained and will again be tested for 
adipokines.  At each visit, weight and height will be measured as per their routine follow-up 
care.  
SPECIMEN PROCESSING AND EVALUATION 
Patient blood work including LFTs, HbgA1C, insulin, glucose, lipid panel, VitD, and PTH levels will 
be processed and performed by the core laboratory.  Circulating adipokine levels will be 
determined using ELISA assays in the Wong Laboratory. Adipose tissue will also be processed in 
the Wong Laboratory.  RNA extraction of the adipose tissue will be performed using the Trizol 
method and mRNA expression will be measured using Real-Time PCR methods to evaluate 
expression levels of the VDR, 1alpha hydroxylase enzyme, and adipokines, including adiponectin, 
leptin, and CTRPs.  Healthy control tissue (n=10) will be obtained from the National Disease 
Research Interchange for study comparison.  Protein levels of the VDR and 1α-hydroxylase 
enzyme will be assessed using Western Blot. 
STATISTICAL ANALYSIS 
Student’s t-test or Wilcoxon rank sum will be used to compare the expression of VitD and 
adipokines between the two groups (obese vs. lean fat).  Correlations between VitD status and 
adipokines will be analyzed using Pearson or Spearman’s correlations.  Longitudinal methods 
will be utilized to assess VitD status and adipokine expression across different time points. VitD 
status and continuous variables (BMI, LFTs, HbgA1C, insulin, glucose, lipids, and PTH levels) in 
obese patients will be analyzed using Pearson or Spearman’s correlations, and linear regression 
models. Stratification and subset analysis will be performed for study patients with and without 
diabetes, heart disease, and liver disease. 
Our protocol has been approved by our institution’s IRB (NA_00085888) with the exception of 
the analysis of VitD metabolites and PTH, which we are adding through a Change In Research 
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submission to our Institutional Review Board.  Subjects will be consented according to our IRB 
policy on informed consent. 
RESPONSIBILITY AND ROLE IN RESEARCH PROJECTS 
Leigh Peterson is a PhD Candidate at the Johns Hopkins School of Public Health (JHSPH) in the 
Department of International Health in the Program on Human Nutrition and is the Senior 
Research Program Coordinator for The Center for Bariatric Surgery at the Bayview Medical 
Center. She has extensive experience in clinical studies, i.e. designing, implementing, database 
management, and recruiting.  In addition, Mrs. Peterson holds a Master of Health Science in 
Molecular, Microbiology, and Immunology also from the JHSPH and has basic laboratory 
experience. She will be responsible for patient recruitment and follow-up, specimen 
procurement, database maintenance, and statistical support.  
Risa Wolf is a pediatric endocrine fellow and a post-doctoral research fellow in the Wong 
Laboratory in the Center for Metabolism and Obesity Research at the Johns Hopkins School of 
Medicine.  As part of the Wong Laboratory, Dr. Wolf has extensive experience in studying 
adipokine function in the context of metabolism. She will be responsible for performing the 
ELISA testing and tissue processing in the laboratory.  Human specimens will be obtained, stored 
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My research interests are in the intersection of nutrition and immune competence. More 
specifically, I am interested in the role of vitamin D as an immunomodulator in the following 
areas: 
 
1. Photoproduction of vitamin D and skin cancer risk: a false paradox? 
2. Supplementation vs. photoproduction
3. Delayed wound healing 
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a. Skin 
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7. Negative pregnancy outcomes 
a. Preeclampsia 
b. Spontaneous preterm birth 
c. Gestational diabetes 
d. Fetal growth restriction 
e. Fetal and infant survival 
8. Maternal-child relationship 
a. Immune tolerance malformation leading to increased incidence of 
i. Autoimmunity 
ii. Food allergy 
b. Inflammation 
c. Infection 
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